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Background: Caesarean section is associated with blood loss and maternal morbidity. Excessive blood loss
requires transfusion of donor (allogeneic) blood, which is a finite resource. Cell salvage returns blood lost
during surgery to the mother. It may avoid the need for donor blood transfusion, but reliable evidence of
its effects is lacking.
Objectives: To determine if routine use of cell salvage during caesarean section in mothers at risk of
haemorrhage reduces the rates of blood transfusion and postpartum maternal morbidity, and is
cost-effective, in comparison with standard practice without routine salvage use.
Design: Individually randomised controlled, multicentre trial with cost-effectiveness analysis. Treatment
was not blinded.
Setting: A total of 26 UK obstetric units.
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Participants: Out of 3054 women recruited between June 2013 and April 2016, we randomly assigned
3028 women at risk of haemorrhage to cell salvage or routine care. Randomisation was stratified using
random permuted blocks of variable sizes. Of these, 1672 had emergency and 1356 had elective
caesareans. We excluded women for whom cell salvage or donor blood transfusion was contraindicated.
Interventions: Cell salvage (intervention) versus routine care without salvage (control). In the intervention
group, salvage was set up in 95.6% of the women and, of these, 50.8% had salvaged blood returned.
In the control group, 3.9% had salvage deployed.
Main outcome measures: Primary – donor blood transfusion. Secondary – units of donor blood
transfused, time to mobilisation, length of hospitalisation, mean fall in haemoglobin, fetomaternal
haemorrhage (FMH) measured by Kleihauer–Betke test, and maternal fatigue. Analyses were adjusted for
stratification factors and other factors that were believed to be prognostic a priori. Cost-effectiveness
outcomes – costs of resources and service provision taking the UK NHS perspective.
Results: We analysed 1498 and 1492 participants in the intervention and control groups, respectively.
Overall, the transfusion rate was 2.5% in the intervention group and 3.5% in the control group [adjusted
odds ratio (OR) 0.65, 95% confidence interval (CI) 0.42 to 1.01; p = 0.056]. In a planned subgroup
analysis, the transfusion rate was 3.0% in the intervention group and 4.6% in the control group among
emergency caesareans (adjusted OR 0.58, 95% CI 0.34 to 0.99), whereas it was 1.8% in the intervention
group and 2.2% in the control group among elective caesareans (adjusted OR 0.83, 95% CI 0.38 to 1.83)
(interaction p = 0.46, suggesting that the difference in effect between subgroups was not statistically
significant). Secondary outcomes did not differ between groups, except for FMH, which was higher under
salvage in rhesus D (RhD)-negative women with RhD-positive babies (25.6% vs. 10.5%, adjusted OR 5.63,
95% CI 1.43 to 22.14; p = 0.013). No case of amniotic fluid embolism was observed. The additional cost
of routine cell salvage during caesarean was estimated, on average, at £8110 per donor blood transfusion
avoided.
Conclusions: The modest evidence for an effect of routine use of cell salvage during caesarean section on
rates of donor blood transfusion was associated with increased FMH, which emphasises the need for
adherence to guidance on anti-D prophylaxis. We are unable to comment on long-term antibody sensitisation
effects. Based on the findings of this trial, cell salvage is unlikely to be considered cost-effective.
Future work: Research into risk of alloimmunisation among women exposed to cell salvage is needed.
Trial registration: Current Controlled Trials ISRCTN66118656.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 2.
See the NIHR Journals Library website for further project information.
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Plain English summary
Mothers delivering by caesarean section bleed heavily at times. In this situation, unless they get a donorblood transfusion, their life is put at risk. Donor blood for transfusion is a limited resource and,
despite many advances, people who receive donor blood can sometimes experience adverse reactions.
Blood transfusions should be given only when absolutely necessary and alternatives should be used
wherever available.
Nowadays, it is possible to use cell salvage. This is a process by which the blood that a patient loses at
surgery is collected by a machine, cleaned and returned to them. In women who have caesarean sections,
this might avoid the need for donor blood, reduce the risk of complications and potentially cut costs. We
conducted this study to evaluate the effects of routine use of cell salvage in caesarean section compared
with standard care when this is not routinely done.
This study included more than 3000 mothers giving birth by caesarean section. Half of these were randomly
selected to receive cell salvage, meaning that the cell salvage was set up to collect blood lost. Cell salvage
was found to be safe. It slightly reduced the use of blood transfusions. For every 100 mothers given cell
salvage, one avoided donor blood transfusion. If the blood groups of the mother and the baby were
mismatched, mothers with a negative blood group needed additional treatment to avoid complications in
future pregnancies. This can be easily monitored and provided as part of routine care. Based on the results
of this study, cell salvage is unlikely to be considered cost-effective.
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Scientific summary
Background
Excessive blood loss (haemorrhage) in childbirth is an important direct cause of maternal death and has a
profound impact on survivors. It is responsible for the majority of emergency hysterectomies and maternal
critical care admissions. Haemorrhage is more common in women undergoing a caesarean section, particularly
in the presence of placental abnormalities (placenta praevia/accreta), pre-eclampsia, antepartum haemorrhage,
a history of previous caesarean section(s), or emergency caesarean for any indication. Approximately 166,000
caesarean sections (26% of all deliveries) are performed annually in England, around 60% of which are
emergency procedures. It is the most frequent major surgery conducted by the UK NHS. Major haemorrhage
can occur without warning during caesarean section with rapid unanticipated deterioration requiring
urgent response.
The treatment for major haemorrhage involves donor blood transfusion when the operative loss is
life-threatening or when the mother has severe anaemia following arrest of the haemorrhage. Red cell
concentrate is a limited resource and is in demand by many clinical services. The high frequency of
caesarean sections has a major impact on blood transfusion services (with £7M direct cost for donor blood
components alone used in the obstetric setting per year), placing a constant challenge at the delivery of
high-quality health care at all points of need simultaneously. There has also been a major shift to more
restrictive clinical transfusion practice aligned to the principles of patient blood management, which include
using transfusion alternatives when feasible and harnessing the patient’s own reserves. Accordingly, donor
blood is used sparingly in the healthy obstetric population. This can result in anaemia postnatally, which is
potentially associated with longer recovery, increasing hospitalisation costs and wound infection rates.
Intraoperative cell salvage collects the woman’s own blood that has been lost during caesarean, processes
it and returns it to her circulation. It reduces the infectious and allergenic risks associated with donor
blood transfusion. It can be used routinely for moderate blood loss, which is an expected feature of
uncomplicated caesarean sections, returning all salvaged blood to minimise postoperative anaemia and its
consequences, including reduction in maternal life quality. Cell salvage has been shown to reduce the
amount of donor blood given in other operations from a wide spectrum of surgical disciplines, but has
hitherto been considered relatively contraindicated for use in obstetrics as a result of theoretical concerns
around the risk of contamination of salvaged blood with amniotic fluid, the potential for provoking
maternal amniotic fluid embolism (AFE) and the possibility of increasing exposure of the mother to fetal
blood. Concerns about AFE have proven unfounded, as research has not only shown that modern
equipment effectively removes amniotic fluid from the salvaged blood, but also that transfer of amniotic
fluid into the maternal circulation is a common event during birth that does not usually cause any adverse
effects. Cell salvage has begun to enter use in caesarean section, but opinion about its value is not yet
evidence based.
Objectives
The primary objective of the trial was to determine whether or not the routine use of cell salvage during
caesarean section in women at risk of haemorrhage safely reduced the need for donor blood transfusion,
in comparison with standard practice when salvage is not routinely used. In addition, we sought to assess
the consistency of the effect of cell salvage across subgroups defined by indication for caesarean and to
determine the effect of cell salvage on secondary outcomes, including the units of donor blood transfused,
fall in perioperative haemoglobin concentration, any resulting morbidity, maternal exposure to fetal blood
and the cost-effectiveness of cell salvage.
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Methods
The cell SALVage in Obstetrics (SALVO) study was designed as a multicentre individually randomised
controlled trial (registered as ISRCTN66118656) with cost-effectiveness analysis. Following the necessary
approvals (UK ethics approval number 12/NW/0513), the study was conducted in 26 obstetric units across
the UK, aiming to recruit 3050 women to give 80% power to detect a 2% difference in the transfusion
rate (control event rate of 5%). Our sample consisted of women who were admitted to the labour ward
for delivery by emergency (category 1–3: with an element of maternal or fetal compromise) or elective
(category 4: no maternal or fetal compromise) caesarean section, with an identifiable increased risk of
haemorrhage, who were at least 16 years old and able to understand written and spoken English. We
excluded women undergoing an elective first caesarean owing to either maternal request or known breech
presentation, as the risk of severe haemorrhage is very low in these groups. We also excluded women for
whom either cell salvage or donor blood transfusion was contraindicated, including those with sickle cell
disease or trait, active malignancy (such as abdominal cancer), religious or other beliefs precluding blood
transfusion, or significant maternal antibodies making it difficult to find cross-matched blood compatible
for transfusion.
For all women undergoing elective caesarean section, information about the study was provided at least
1 day before the surgery, usually at the time of booking the caesarean section; written informed consent
for the study was then obtained before the surgery. For women undergoing emergency caesarean section,
either written informed consent was obtained before the surgery, if there was sufficient time for discussion
and reflection, or otherwise verbal consent was taken immediately before the surgery with written consent
obtained after the operation, usually on the postnatal ward. In either case, in order for consent to be
properly informed, the woman either (1) had to have received information antenatally before the onset
of labour and previously stated her willingness to take part in the study or (2) following a substantial
amendment to the protocol, had sufficient time and was not too distressed to receive study information
after admission to the labour ward (this was deemed to be the case if the woman was comfortable with
effective epidural analgesia in situ, or not yet in established first stage of labour, and had at least 1 hour
to come to a decision after receiving the information and prior to giving verbal consent). Participating
women were randomised by entry into an online system to either caesarean section with cell salvage,
with cell-saver set-up and collection of shed blood from the outset of surgery and return of any processed
blood obtained (intervention group), or to caesarean section without cell salvage, with transfusion of
donor blood according to local guidelines (control group).
The primary outcome was the proportion of women receiving donor blood transfusion due to haemorrhage.
Trial groups were compared according to this outcome on an intention-to-treat basis, estimating the effect
using odds ratios (ORs) and 95% confidence intervals (CI). Two prespecified subgroup analyses were
planned, including analysis of treatment effect by indication for caesarean section (elective or emergency)
and by treatment centre. The first of these was analysed by statistically testing for an interaction between
indication for caesarean section and treatment. The second was analysed by testing for a random regression
coefficient for the effect of treatment at different centres, in addition to a random intercept. In order to
account for women in the control group who received cell salvage due to a clinical decision, an additional
sensitivity analysis was planned that would assume that all instances of return of salvaged blood in the
control group would have been instances of donor blood transfusion had the cell salvage machine not been
present. Analyses were adjusted for a random effect of treatment centre and fixed effects of stratification
variables and other baseline characteristics believed to be associated with the outcome measure of
haemorrhage a priori.
Secondary outcomes included units of blood transfused, time to first mobilisation, length of hospital stay,
pre and postoperative serum haemoglobin, maternal exposure to fetal blood as measured by a Kleihauer–
Betke test, maternal fatigue, adverse events (including transfusion reactions), resources used intraoperatively
and postoperatively, costs of staff training, and process outcomes (including volume of salvaged blood
returned and technical failure of cell salvage).
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A cost-effectiveness analysis was carried out from the NHS perspective based on the principal clinical
outcome of the trial with the results expressed as cost to avoid donor blood transfusion. A decision tree
model was used, which collated all the relevant resource use, cost and outcome data collected prospectively
during the trial to compare the overall cost-effectiveness of cell salvage with standard care. The resource
use for both groups of the trial was estimated by evaluating the individual components of these procedures
(bottom-up costing). Unit cost data were then attached to the resource use. A probabilistic sensitivity
analysis was carried out to explore the effects of the inherent uncertainty in parameter estimates on
model results.
Results
Between June 2013 and April 2016, 3054 participants requiring caesarean section from 26 participating
hospitals were initially recruited for randomisation. After 26 exclusions for eligibility and consent issues,
3028 participants were randomly allocated to either control (n = 1511) or intervention (n = 1517). Of these
3028 participants, 1672 were scheduled for emergency and 1356 for elective caesarean section. A further
35 participants had to be excluded after randomisation owing to vaginal delivery or transfer to another site.
We analysed data from 1492 participants in the control group and 1498 participants in the cell salvage
group, after these exclusions for eligibility and loss to follow-up. Adherence to assigned intervention was
95.6% in the cell salvage group and 96.1% in the control group. Among the women treated with cell
salvage in the intervention group, 50.8% had salvaged blood returned, with an average volume of 259.9 ml.
Overall, the transfusion rate was 2.5% in the group assigned to cell salvage and 3.5% in the control group
(adjusted OR 0.65, 95% CI 0.42 to 1.01; p = 0.056). In the planned subgroup analysis, the transfusion
rate was 3.0% in women assigned to salvage and 4.6% in the control group among emergency caesareans
(adjusted OR 0.58, 95% CI 0.34 to 0.99), whereas it was 1.8% in the intervention group versus 2.2% in
the control group among elective caesareans (adjusted OR 0.83, 95% CI 0.38 to 1.83) (interaction p = 0.46,
suggesting that the difference in effect between subgroups was not statistically significant). In an additional,
exploratory, subgroup analysis, the transfusion rate was 1.9% in women assigned to the salvage group
and 2.9% in the control group among caesareans with normal placentation (adjusted OR 0.56, 95% CI
0.34 to 0.94), whereas it was 9.6% versus 8.9% among caesareans with abnormal placentation (adjusted
OR 0.83, 95% CI 0.38 to 1.83) (interaction p = 0.28). A sensitivity analysis assuming that donor blood
transfusion would have been required had cell salvage not been deployed in the control group showed a
reduction in the proportion of participants requiring donor blood transfusion (5.6% vs. 2.5%, adjusted OR
0.39, 95% CI 0.26 to 0.59; p < 0.001).
There were small differences between groups for time to mobilisation [median 0.74 vs. 0.72 days, adjusted
hazard ratio (HR) 1.11, 95% CI 1.03 to 1.19; p = 0.006] and length of hospital stay (2.131 vs. 2.126 days,
adjusted HR 1.08, 95% CI 1.00 to 1.16; p = 0.050). Mothers assigned to cell salvage had greater exposure
to fetal blood than those in the control group (25.6% vs. 10.5%, adjusted OR 5.63, 95% CI 1.43 to
22.14; p = 0.013). There were no differences between groups in other secondary outcomes. There was no
case of AFE observed in any instances of cell salvage use.
The results of the economic evaluation suggested that routine cell salvage is more costly than standard
care with the average cost per patient estimated at £1327 compared with £1244. The incremental
cost-effectiveness ratio representing the average additional cost of routine cell salvage during caesarean
section in women at risk of haemorrhage compared with standard care was estimated to be approximately
£8110 to avoid a donor blood transfusion. This estimate was shown to be robust in sensitivity analyses.
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Conclusions
There was modest evidence for an effect of routine use of cell salvage during caesarean section on the
need for donor blood transfusion, particularly among emergency procedures. In women with rhesus D
(RhD)-negative blood groups who gave birth to RhD-positive babies, cell salvage was associated with
increased maternal exposure to fetal blood, which needs to be matched with higher doses of anti-D if cell
salvage is to be deployed during caesarean sections among RhD-negative mothers. Our finding highlights
the need to adhere to guidelines on anti-D prophylaxis and the need for vigilance also with respect to the
potential sensitisation to other, more rare antibodies. The health economic analysis could not demonstrate
that cell salvage was more cost-effective than standard care. Recommendations for future research include:
1. Investigate the impact of non-rhesus antibody sensitisation with long-term follow-up of mothers
exposed to cell salvage during caesarean section.
2. Investigate the need for greater amounts of routine anti-D administration when cell salvage has
been used.
3. Investigate factors, for example swab washing or number of suckers used, that increase the likelihood
of returning blood during use of cell salvage.
4. Investigate the effectiveness of cell salvage in specific subgroups, for example placenta accreta.
5. Investigate the role of cell salvage in low- to middle-income countries where caesarean rates are rising
and blood transfusion services are not well developed.
6. If new, cheaper or more efficient cell salvage technology becomes available, the conclusions of the
SALVO trial may need to be revisited. The same is true if donor blood shortages should become
extreme and acute.
Trial registration
This trial is registered as ISRCTN66118656.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background and rationale
Haemorrhage and caesarean section
Haemorrhage (excessive blood loss) is an important direct cause of maternal death.1 Life-threatening blood
loss is the primary indication for 95.6% of emergency hysterectomies in labour.2 Haemorrhage is the
most common cause for maternal critical care admission3–5 and places a profound health burden on the
childbearing population during an important life event. Haemorrhage is more common in women who
have caesarean sections,6 particularly when indicated for conditions such as placenta praevia (low-lying
placenta) or when an emergency caesarean section is required.7
Approximately 166,000 caesarean sections are performed annually in England. Almost two-thirds of
these are performed as emergency procedures and the number of operations has been ever increasing.8
Caesarean section currently accounts for 26.2% of deliveries (2013–14) and it is the most frequent major
operation conducted by the NHS, with > 400 performed per day in England alone.9 Major haemorrhage can
occur without warning during caesarean section and the woman’s condition can quickly deteriorate during
attempts to arrest blood loss. Rates of major obstetric haemorrhage vary in the literature according to the
definition used; postpartum haemorrhage (PPH) occurs with a frequency of 2.93%6 but severe PPH of ≥ 2.5
is much less common, with a frequency of around 0.5–0.6%.10 The likelihood of haemorrhage is increased
by risk factors including previous caesarean section, low-lying or morbidly adherent placenta, emergency
caesarean section for any indication, antepartum haemorrhage and pre-eclampsia.6,10
Donor blood transfusion in obstetrics
The treatment for major haemorrhage involves allogeneic (donor) blood transfusion when the operative
loss is life-threatening or when the mother has severe anaemia following arrest of the haemorrhage.
Approximately 66,000 units of blood (known as packed red cells) are given annually in the UK maternity
setting.11 This equates to £7M per year12 without considering additional health-care costs involved in the
administration of blood or the financial consequences of maternal acute illness. Thus, any reduction in the
amount of blood required for obstetrics could significantly reduce the cost of blood transfusions.
Donor blood is a limited resource that needs to be used judiciously. Although national blood services are
constantly improving their capacity to guarantee availability of blood for transfusion across all clinical
requirements,13 it remains an expensive service to recruit and retain blood donors to minimise the risks of
shortages, and new infective risks may arise in future. The availability of donor blood is an essential
prerequisite for major procedures including joint replacement, cardiac surgery, organ transplantation,
cancer care, obstetric emergencies and the management of trauma. This wide range of demands provides
significant challenges to the NHS in the delivery of high-quality health care to all points of need
simultaneously. All NHS hospitals are required to have policies for blood shortages, including cancellation
of elective surgeries that may require transfusion.
There is an increasing focus on patient blood management, an international initiative promoting the use of
transfusion alternatives including cell salvage, when feasible, and limiting the use of donor transfusion
when avoidable.14,15 Transfusion sparing strategies successful in other surgical populations, such as
pre-donation and acute normovolaemic haemodilution, cannot be employed in caesarean section. The role
of permissive anaemia and high transfusion threshold is potentially limited by maternal symptoms in the
postnatal period (see Postnatal anaemia and its consequences).
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In addition, there are major risks associated with donor blood transfusion, including death from transfusion
error, acute transfusion reaction, fatal lung injury and infection transmission.16 These risks are monitored by
the UK haemovigilance scheme, Serious Hazards Of Transfusion (SHOT), with feedback of results via annual
reports.17 Despite improved safety mechanisms, these rates persist, although serious events are very rare,
with mortality rates of 1 in 100,000.18 Nevertheless, minimising unnecessary transfusion is an important
strand in promoting patient safety.
Postnatal anaemia and its consequences
Concerns regarding transfusion safety together with changes in clinical practice, as highlighted in
Donor blood transfusion in obstetrics, have led to a more overall restrictive approach to transfusion.
The application of these principles to the obstetric setting with higher transfusion thresholds can result
in significant postnatal maternal anaemia.
In addition to fatigue as a direct consequence, postoperative maternal anaemia has been associated with
longer hospitalisation, increased wound infection rates and delayed time to mobility.19 Anaemia prolongs
hospital stay by one-third, with an overall 50% higher cost per hospitalisation.20 The economic consequences
of anaemia resulting from obstetric haemorrhage are therefore profound and any intervention that could
reduce maternal morbidity and mortality is worthy of scrutiny.
Maternal morbidity resulting from anaemia crucially affects the mother’s capacity to provide care for the
newborn. An intervention to relieve maternal anaemia is therefore highly relevant for the quality of life of
this young, generally healthy population of mothers and that of their offspring.
Intraoperative cell salvage
Intraoperative cell salvage collects the patient’s own blood lost during an operation, processes it and
returns it to their circulation. This way, cell salvage allows retransfusion of the patient’s own blood that
would otherwise have been wasted.
Its use has been shown to reduce the amount of donor blood given in other operations. A Cochrane review
and other meta-analyses of the use of cell salvage in non-obstetric settings demonstrated a significant
reduction in patient exposure to donor blood.21 A Health Technology Assessment (HTA) report put the
relative risk (RR) of exposure to donor blood at 0.59 [95% confidence interval (CI) 0.48 to 0.73] for pooled
trials of cell salvage.22 However, this evidence did not include any trials examining caesarean section.
Given that cell salvage may reduce the need for a standard donor blood transfusion, there should be fewer
transfusion reactions and infections that may be associated with donor blood. One potential complication
associated with cell salvage in the non-obstetric setting arises owing to the use of leucocyte depletion
filters (LDFs) during the return of salvaged blood.17,23–26 LDFs are used in the retransfusion of salvaged
blood with the aim of filtering out foreign cells, such as squamous cells contained within amniotic fluid.
They have been the subject of scrutiny in the medical literature. There are some reports of unexplained
hypotension associated with blood return and filters have been implicated as a potential source of most
anaphylactoid responses (although this remains a contentious issue and, in rare cases, hypotension has
been associated with cell salvage even when no LDF was used).17 Moreover, the addition of a filter may
restrict the rapid reinfusion of blood in the context of massive haemorrhage by slowing down the blood
flow rate. Therefore, these filters are routinely omitted at the discretion of clinicians when rapid blood
return is imperative.
Overall, cell salvage is a technology that may simultaneously reduce the need for donor blood transfusion
and prevent anaemia. Therefore, it could avoid the serious morbidity associated with haemorrhage as well
as achieve a significant reduction in costs. In recent years, cell salvage machines have been refined and
have entered routine use in cardiac, orthopaedic, liver and vascular surgery for which there is a risk of
major haemorrhage. Their use in caesarean section has not yet been adequately examined.
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Cell salvage in caesarean section
Moderate blood loss is a normal expectation during uncomplicated caesarean section. By salvaging this
blood, it may be returned to the patient, even when donor blood transfusion would not normally be
considered for the reasons already discussed. This might further serve to reduce postnatal anaemia and its
associated morbidity, thus benefiting mothers who lose only a moderate amount of blood during caesarean
section and who would not normally be considered for a donor blood transfusion.
The use of cell salvage in the obstetric setting had previously been considered contraindicated as a result
of theoretical concerns regarding the risk of amniotic fluid embolism (AFE), a serious but extremely rare
(about 1 in 20,000) complication of pregnancy and childbirth. Its pathophysiology is more similar to
anaphylaxis than to embolism. AFE is usually diagnosed at autopsy when fetal squamous cells are found in
the maternal lungs, but fetal cells are also found in the circulation of labouring women who do not
develop the typical clinical features of AFE. Although the term is controversial, the complications of AFE are
attributed to multiorgan failure and maternal fatality. Studies examining the quality of blood that would be
returned to the mother, if cell salvage had been used at caesarean section, have shown that there is no
safety concern with modern equipment as amniotic fluid is both effectively and completely removed by cell
salvage processing.27,28 Despite concerns about AFE as a consequence of cell salvage having proven
unfounded in research thus far,27,28 and evidence that the transfer of amniotic fluid into the maternal
circulation is a common event that does not necessarily cause adverse effects,29–32 this issue remains of
concern to clinicians.
Another potential risk associated with cell salvage in the obstetric setting is sensitisation to red cell
antigens leading to haemolytic disease of the fetus and newborn (HDFN).33,34 This occurs when there is an
incompatibility between antigens carried on red blood cells (RBCs) of a woman and her infant, with the
rhesus D (RhD) antigen being one of the most important. In a RhD-negative woman carrying a RhD-positive
baby, fetal red cells entering the maternal circulation may provoke an immune response in the maternal
immune system. These antibodies can then result in severe fetal and neonatal haemolytic disease in future
pregnancies. All RhD-negative unsensitised women delivering a RhD-positive baby should be routinely
offered a standard dose of anti-D immunoglobulin [at least 500 international units (IU)] as prophylaxis to
minimise this risk of sensitisation.
A test for fetomaternal haemorrhage (FMH) is recommended to quantify the volume of fetal red cells that
have entered the maternal circulation and determine if additional doses of anti-D immunoglobulin are
indicated. The Kleihauer–Betke (hereafter referred to as Kleihauer) test is a manual test undertaken in
hospital transfusion laboratories as an initial screen to assess the volume of FMH. As this test is associated
with a high coefficient of variation, referral for more specialist testing with flow cytometry is recommended
for accurate confirmation if the FMH is estimated to be ≥ 2 ml by the Kleihauer test.
The volume of fetal red cells in maternal blood following cell salvage is variable but can be relatively
large. Accordingly, updated UK guidelines from the British Society of Haematology published in 201434
recommend a minimum anti-D immunoglobulin (Ig) dose of 1500 IU to be administered after reinfusion of
salvaged red cells. FMH testing, as above, should indicate if any additional doses of anti-D Ig are required.
Antibodies to other red cell antigens are also implicated in causing HDFN.35 These may have consequences
for future pregnancies or long-term blood transfusion. Although there is no evidence to suggest that cell
salvage increases the risk of sensitisation, this topic has not been specifically addressed in studies to
date,36,37 but merits further scrutiny.
The National Institute for Health and Care Excellence (NICE) currently only recommends cell salvage for
obstetrics in the emergency management of massive haemorrhage in caesarean section, but has called
for robust evidence from clinical trials to support its wider, routine use.38 The guideline38 states that the
technology may be of benefit with careful patient selection, for example caesarean or vaginal delivery in
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cases with known placenta praevia or placenta accreta. Selective use of cell salvage in obstetrics is also
recommended by obstetric and anaesthetic professional bodies.39,40
Cell salvage is beginning to enter routine use in caesarean section in some hospitals, with the aim of
realising some of the benefits known from other settings. A national survey conducted in 2005–6 reported
that 38% of UK maternity units had access to cell salvage and 12% included it in their major obstetric
haemorrhage protocol.41 By 2011, this had increased to 49% of UK maternity units having access to cell
salvage.42 However, use in this context remains unproven and is not supported by evidence for its clinical
or economic effectiveness. Opinion had not yet solidified in the clinical community and clinicians who were
engaged in preparation for the cell SALVage in Obstetrics (SALVO) trial showed that the need to launch a
large multicentre randomised controlled trial (RCT) to generate reliable, valid, evidence was recognised.
Cost considerations
Caesarean section is a frequently performed operation and the cost per patient of consumables used in
routine cell salvage is approximately the same as a single unit of blood. This must be set against the cost
of blood transfusion, the care costs of prolonged hospital stay and the expense of treating adverse events
(AEs) associated with transfusion. Cell salvage could realise the dual economic goals of earlier hospital
discharge and enhanced maternal quality of life.
Existing evidence
We published43 and updated36 a systematic review that identified one small controlled trial of cell salvage
in caesarean section in Italy, with 34 participants in each group, which reported a significant reduction in
the number of participants requiring transfusion in the cell salvage group.44 However, there were flaws in
trial design and conduct, including no explanation of the randomisation method. Furthermore, the control
group transfusion rate of 23.5% was at least four times greater than normal practice in the UK. The
methodology employed in other studies, including a retrospective review,45 case series and isolated case
reports,46–54 precluded definitive conclusions but supported the safety of cell salvage in obstetrics.
The above-mentioned NICE review of cell salvage38 focused on the lack of high-quality research and called
for RCTs. The Royal College of Obstetricians and Gynaecologists (RCOG) guidelines of 200740 recognised
that cell salvage in obstetrics remained controversial. The evidence was graded C as a result of the absence
of robust trials on which to base recommendations.
An economic model, drawn from primary cost studies and randomised trials, concluded that cell salvage
had lower costs and higher quality-adjusted life-years (QALYs) than all other alternative transfusion
strategies, except acute normovolaemic haemodilution.22 However, this model did not include caesarean
section, limiting generalisability to the obstetric setting.
A pilot RCT of cell salvage in elective (planned) caesarean section was performed at one prospective SALVO
participating centre55 to help refine the trial processes and assess feasibility. At closure, 57 women undergoing
elective caesarean section had been randomised. The consent rate was 71% of women approached. The
primary outcome data were collected for 100% of randomised women. The use of cell salvage was feasible
and acceptable to staff and to the women who were randomised. Blood salvage and return was technically
unproblematic, requiring minimal additional resource. Out of the 30 women who were randomised to cell
salvage, it was set up and deployed in 28 women (93%), with sufficient blood collected to enable return of
an average of 284 ml (SD 113 ml) of blood to five women. Adherence to the randomisation strategy was
high with one case of use of cell salvage in the control group, following intraoperative haemorrhage due to
undiagnosed placenta accreta. No woman in the cell salvage group required allogeneic transfusion but one
woman (3.7%) in the routine treatment group, with an undiagnosed placenta accreta, received two units of
allogeneic blood.
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Objectives
The primary objective of the SALVO trial was to determine if the routine use of cell salvage during both
elective and emergency caesarean section, in women at risk of haemorrhage, reduced the need for donor
blood transfusion in comparison with current practice, for which salvage is not routinely used. In addition,
we sought to assess the consistency of the effect across subgroups defined by indication for caesarean,
and to determine the effect on secondary outcomes including the number of units of donor blood
transfused, fall in haemoglobin level, maternal morbidity resulting from postoperative anaemia (time to first
mobilisation, duration of hospital stay and postnatal fatigue), maternal exposure to fetal blood, and its
cost-effectiveness in comparison with current practice.
DOI: 10.3310/hta22020 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 2
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Khan et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
5
Chapter 2 Methods
Trial design
The SALVO trial was a multicentre individually randomised controlled trial with cost-effectiveness analysis.
Setting
The trial was conducted in 26 hospitals with large obstetric units, in 23 NHS Trusts in England, Wales and
Scotland (see Appendix 1 for a list of sites). These units each cared for between 3800 and 8000 births
annually and performed between 900 and 2000 caesarean sections per year.
Participants
Eligibility criteria
Inclusion criteria
Women who were admitted to a participating labour ward and who fulfilled all of the following inclusion
criteria were eligible to be randomised:
l being aged ≥ 16 years
l having the ability to provide informed consent
l undergoing delivery by caesarean section with an identifiable increased risk of haemorrhage, defined as
all emergency caesarean sections, and elective caesarean section for all indications other than maternal
request or breech presentation.
A number of systems for classifying the urgency of caesarean section have been suggested,56 both to
improve communication between health-care professionals and to assign maximum time intervals for audit
purposes between decision for performing caesarean section and actually carrying out the delivery.57,58 The
classification system recommended by the RCOG57 was in use in the UK hospitals during the SALVO trial.
For stratification purposes, the important distinction for our purposes was between elective (category 4:
no maternal or fetal compromise and timing to suit the woman and maternity services), which has a lower
incidence of haemorrhage and transfusion, and emergency categories. We use the term emergency to
mean caesareans distinct from the elective category, in that early delivery was mandated clinically. In this
category, the immediacy of threat to life of woman or fetus varies and accordingly the urgency to deliver
varies too (category 1: immediate threat and timing immediate; categories 2 and 3: no immediate threat and
timing flexible depending of assessment of maternal or fetal compromise). We have avoided the use of words
such as crash, urgent and scheduled, as these have different meanings in different classification systems.
Abnormality of placentation was based on the degree of abnormal myometrial invasion (placenta accreta,
increta and percreta) and the localisation of its insertion within the lower uterine segment (placenta
praevia major or minor) as assessed by antenatal ultrasonography examination. In these circumstances,
current guidelines suggest that cell salvage may be considered in women who are at a high risk of massive
haemorrhage, especially in women who would refuse donor blood. Routine use in these cases is not
recommended.
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Exclusion criteria
l Elective first caesarean section for maternal request or breech presentation, with no additional
prognostic factor for haemorrhage. Maternal request included women with personal reasons for
wishing to avoid vaginal delivery, such as previous traumatic delivery, or psychiatric or psychological
problems. These indications do not put the mother at increased risk of haemorrhage. All other
indications for caesarean sections, including all emergency cases, were considered an identifiable
increased risk of haemorrhage.
l Sickle cell disease or trait. Use of cell salvage may lead to the presence of abnormal RBCs, which can
deform and block the microscopic blood vessels in the body, leading to a sickle cell ‘crisis’. Even if this
is only in the trait form, there is an increased chance that this ‘sickling’ may occur while the blood is in
the cell salvage collection reservoir awaiting processing owing to the low oxygen levels and, thus, a risk
that a sickle cell crisis could be precipitated if this blood is returned to the woman.
l Active malignancy contraindicated to caesarean section, especially cancer in the abdominal region, as
there is a theoretical risk of spreading the cancer should cell salvage be used.
l Cultural or religious beliefs contraindicating blood transfusion (e.g. Jehovah’s Witnesses), as donor RBC
transfusion was the primary study outcome.
l Significant antibodies making it difficult to find cross-matched blood for transfusion. This is because
allogeneic blood for this group of patients is likely to be scarce or unavailable. We considered it
appropriate to give these patients cell salvage from the start of their case.
l Inability to understand written and spoken English.
In some circumstances, some of the participating sites applied clinical judgement not to recruit patients
with a high risk of haemorrhage and instead preferred to use cell salvage a priori outside the study.
Screening and consent procedures
Screening and antenatal information
In addition to participant information sheets and informed consent forms, we provided sites with short
patient pamphlets (which were used to provide information about the study during the antenatal period)
as well as posters. All patient recruitment materials were approved by the Research Ethics Committee (REC)
prior to use.
Information about the study was distributed to as many women as possible who were ‘booked’ to deliver
at participating centres during their pregnancy and again on admission to delivery suite, whether they
were intending a normal (vaginal) delivery or an elective caesarean section. This process was individualised
at each participating centre depending on their routine practice to ensure that the maximum number of
women were offered information well in advance of delivery. In some centres, women were provided with
information about the trial at their routine anomaly scan appointment at 18–22 weeks’ gestation. The
provision of study information was documented in the woman’s medical record or handheld notes and
a sticker applied to indicate whether or not she was interested in taking part in the study. It was also
documented at this point whether or not they would still be interested in taking part in the study in an
emergency situation. Written informed consent was obtained by a trained health professional (obstetrician,
anaesthetist or midwife) with delegated authority from the principal investigator. All women were assessed
to ensure that they had the capacity to provide consent. The process and timing for obtaining written
consent varied according to clinical urgency (see Figure 1).
Recruiting women undergoing elective caesarean section
Eligible women requiring elective caesarean section were provided with further information and the
opportunity to ask questions at the time the operation was booked. They were then approached for
written consent at the preoperative assessment clinic or on the day of surgery. Randomisation took place
on the day of surgery.
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Recruiting women undergoing emergency caesarean section
Women who were booked for delivery received information regarding the trial during their pregnancy so
that there was sufficient time to consider participation in the trial, should an emergency caesarean section
be required. On admission to delivery suite, women’s notes were checked to ensure this information had
been supplied and the opportunity for further discussion provided.
After recruitment of half of the required target sample, a substantial protocol amendment was submitted
and approved in order to facilitate recruitment of women undergoing emergency caesarean section. This
allowed women to be approached for the first time on the delivery suite if they were found to be in the
latent stage of labour (i.e. not yet in established first stage of labour according to NICE guidelines59,60)
or were comfortable with epidural analgesia, provided that all of the following criteria were fulfilled.
l They were willing to receive the trial information and were subsequently willing to discuss the
participant information sheet and have any questions answered if desired.
l They had either 0- to 3-cm cervical dilatation and were not contracting regularly (i.e. a maximum of
one contraction in 10 minutes, with contraction lasting < 30 seconds) or they were comfortable with
effective epidural analgesia in place.
l They were given at least 1 hour to decide whether or not they would be interested in taking part,
should they require a caesarean section. If their situation changed (i.e. labour became established
during that hour or they were no longer comfortable under epidural analgesia, or required a caesarean
Antenatal clinic (e.g. 18–22 weeks)
Delivery ward
Participant information sheet provided, study explained, questions answered
Eligibility assessed
Written consent obtained
from participant
Verbal consent in
urgent emergency
CS if previously
indicated an
interest to take
part in the study Randomised Enter on enrolment log
Postoperative assessment
Discharge
Participant
reconsent
Caesarean section
with IOCS
Caesarean section with
blood transfusion
Participants information sheet or patient pamphlet provided
Questions answered and further explanation provided if required
FIGURE 1 Consent procedure flow chart. CS, caesarean section; IOCS, intraoperative cell salvage.
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section before the hour elapsed), they were not approached for inclusion. After 1 hour, the women
were approached for further discussion and the opportunity for questions about the study. If the
women had a contraction during the discussion, the health professional involved would pause and wait
for the contraction to finish. Permission to continue with the discussion was then sought.
Women in established labour (i.e. 4-cm cervical dilatation and regular painful contractions), or who were
not comfortable with epidural analgesia, were not approached for the first time on delivery suite. Women
who were distressed and not in a position to absorb the information on the patient leaflet were not
approached for the first time on delivery suite.
Consent was obtained if a decision for caesarean section was made.
Documenting written informed consent
Consent comprised a dated signature from the woman and the dated signature of the person who
obtained informed consent. It was clearly stated that the participant was free to withdraw from the trial at
any time, for any reason, without prejudice to future care and with no obligation to give the reason for
withdrawal. A copy of the signed informed consent document was given to the woman. One copy was
retained in the woman’s medical notes and another by the principal investigator in the investigator site file.
Verbal consent and timing of written informed consent
All participants undergoing elective caesarean section gave written informed consent before the
intervention. Likewise, the majority of emergency caesarean sections in the absence of acute fetal distress
were conducted in a controlled manner with ample time for regional anaesthesia to be established, and
written consent was obtained at this stage once the decision for caesarean section had been made.
In some emergency situations, the urgency meant that there would be insufficient time for written
consent to be obtained prior to the emergency caesarean section. Under these circumstances, if the
woman had the capacity to consent and had previously indicated an interest in taking part in the trial,
verbal consent was obtained by an authorised health professional as described above, and documented on
the randomisation checklist. Written consent was then sought once the urgency of the situation was over
and the caesarean section complete.
Intervention
All staff were sufficiently trained and familiar in the use of the cell salvage machine, in accordance
with local procedures and requirements. The majority of sites used conventional cell-saver machines
with separate set-up for collection and processing of shed blood, whereas some sites used continuous
transfusion systems. To confirm eligibility for randomisation, investigators needed to verify that women
met the inclusion/exclusion criteria for the trial as well as gaining informed consent. An eligibility checklist
was completed prior to randomisation.
Women were randomly allocated to either:
1. caesarean section with cell salvage (intervention group), set up routinely with collection of shed blood
from the outset of surgery and return of any processed blood obtained
2. caesarean section without cell salvage (control group), with transfusion of donor blood according to
standard local guidelines.
The intervention group was treated as follows: blood was aspirated from the surgical field, the red cell
component isolated by centrifugation and retransfused after washing and filtration. The ability to return
salvaged blood is dependent on sufficient volume being collected and processed. Blood was uniformly
returned to women in the cell salvage group if this volume threshold was reached and it was a protocol
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requirement that cell-saver machines were fully set up for both collection and processing upfront at
commencement of surgery and that all available processed blood was retransfused regardless of volume.
The use of a LDF for transfusion of salvaged blood was not mandated as part of the study intervention
protocol, but left up to local guidance. Any reports of severe, unanticipated hypotension and the potential
association with the presence of LDFs were monitored. Likewise, the use of one versus two suction
devices, the latter having one dedicated to amniotic fluid only at uterotomy, as well as salvage machine
‘bowl size’, was at the discretion of the participating site. Swab washing was encouraged, as it was
thought to increase the volume of blood available for processing and, thus, for retransfusion,61 but was
ultimately left to the local investigator’s discretion.
The control group was treated as follows: participants received standard current practice (without cell
salvage) with allogeneic donor blood transfusion as the standard treatment, if required. In life-threatening
acute haemorrhage, women were managed at the discretion of attending clinicians in line with the standard
of care for such an emergency,1,40 potentially including the use of cell salvage in the control group.
Follow-up
Participants were followed up until discharge or transfer from the participating hospital only. Postnatal
investigations included assessment of postoperative haemoglobin levels, collection of multidimensional
fatigue inventory (MFI)62 questionnaires completed by patients (with any missed MFI questionnaires
followed up for completion up to 2 weeks after discharge), documentation of AEs, mobilisation and
discharge times, and, for RhD-negative women with RhD-positive babies, assessment of exposure to fetal
blood by Kleihauer tests and anti-D given.
We took the opportunity to undertake an observational study of practice around anti-D prophylaxis in
RhD-negative women who gave birth to a RhD-positive baby. There are UK guidelines stating that all
RhD-negative women giving birth to a RhD-positive baby should receive a minimum of 500 IU anti-D Ig
as a standard dose following delivery to minimise the risk of RhD alloimmunisation.34 These guidelines,
published in 2014, also recommend that after cell salvage the minimum standard dose should be higher,
at 1500 IU anti-D. The maternal sample should be tested after delivery to assess the level of FMH to guide
if additional anti-D doses are required following the standard dose. In the majority of centres, the
Kleihauer test is undertaken as an initial screening test but, as this is a manual test with a high coefficient
of variation, the guidelines also make further recommendations. Given the crudeness of Kleihauer test
results, these guidelines recommend flow cytometry tests to be performed for Kleihauer test results of
≥ 2 ml, and repeat administrations and repeat testing after 72 hours for any Kleihauer test results of
> 4 ml.63 All centres participating in the SALVO trial would have been expected to have local guidelines on
anti-D prophylaxis. We aimed to collect data around anti-D prophylaxis and FMH testing in all RhD-negative
women recruited to this study to assess current practice. We did not attempt to collect follow-up data on
the development of red cell sensitisation either to the RhD or indeed other red cell antigens in either group,
as this was outside the scope of this particular study.
Outcomes
The primary outcome was the use of donor blood transfusion. Reducing the proportion of women with
this outcome should lead to fewer transfusion-related complications.
Primary outcome
The primary outcome was the proportion of women receiving donor blood transfusion to deal with
haemorrhage and its consequences, either during caesarean section or between surgery and discharge.
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Secondary outcomes
The secondary outcomes analysed included severity of events (quantified as units of donor blood
transfused); time to first mobilisation after caesarean section (calculated as the time from delivery until
documented first mobilisation, i.e. ability of the woman to walk unassisted); length of hospital stay
(calculated as time from delivery until discharge of the mother); pre and postoperative serum haemoglobin;
mean fall in haemoglobin level; maternal exposure to fetal blood (defined as FMH as quantified by
Kleihauer test and defined as a result of ≥ 2 ml, and administration of anti-D antibody); maternal fatigue
measured with the MFI62 [a 20-item self-report questionnaire covering five different dimensions of fatigue
(general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity), in which each
question is scored between 1 and 5, with each of the five fatigue dimensions yielding a maximum score
of 20]; resources used intraoperatively and postoperatively (including cell salvage consumables and donor
blood transfusions); AEs and serious adverse events (SAEs), including proportion of transfusion reactions
associated with allogeneic blood transfusion; and costs of staff training, service procurement and provision
of care, collected alongside clinical outcomes (for full details on health economics methods, see Chapter 4).
In addition, we collected process outcomes including the volume of blood returned in cell salvage, the
proportion of transfusion reaction associated with allogeneic donor blood transfusion and any episodes of
technical failure of cell salvage.
Safety considerations
Adverse events were defined as any untoward medical occurrence in a participant receiving trial
intervention, including occurrences that were not necessarily caused by, or related to, that intervention.
An AE was therefore defined as any unfavourable and unintended sign (including an abnormal laboratory
finding), symptom or disease temporarily associated with study activities.
A SAE was defined as an AE that fulfilled at least one of the following criteria: fatal, life-threatening,
required prolongation of hospitalisation beyond 7 nights after caesarean section for maternal reasons,
resulted in persistent or significant disability, was a congenital anomaly or birth defect, or was otherwise
considered medically significant by the investigator.
The AEs and SAEs were documented if they occurred between randomisation and discharge. They were
only reported if they related to the mother, except for SAEs that fulfilled the criteria of congenital anomaly
above. The local principal investigator responsible for the care of the participant, or in his or her absence
an authorised medic within the research team, was responsible for assessing the severity, causality and
expectedness of an AE, and for assessing whether or not the event was serious according to the
definitions given above.
If an AE was not defined as serious, the AE was documented in the participants’ medical notes (when
appropriate) and on the case report form (CRF). All reported AEs were subject to a central medical review
and coded and grouped by a clinician member of the trial team.
All SAEs occurring during the trial observed by the investigator or reported by the participant, whether or
not attributed to the trial, were documented in the participants’ medical notes (when appropriate) and
reported to the trials office within 24 hours of the site becoming aware of the event. All SAEs were
followed up until resolution or the event being considered stable. The chief investigator, or a delegated
clinical coapplicant, reviewed all SAE reports within 24 hours and raised any queries to be addressed to
the sites. Locally, all serious incidents (such as maternal deaths) occurring at a UK NHS site were subject to
root cause analyses.64
Any SAEs considered both related to the intervention and unexpected were reported to the sponsor and
the pragmatic clinical trials unit (PCTU) quality assurance manager within 24 hours, and to the main REC
within 15 days. Although there were some known or theoretical potential risks associated with the trial
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(including maternal exposure to fetal blood, AFE, severe hypotension and transfusion reaction), none was
considered to fulfil the criteria of being ‘expected’. Therefore, any SAEs that were at least possibly related
to the trial intervention were reported as unexpected SAEs.
If applicable, it was the chief investigator’s responsibility to take any urgent safety measures to ensure the
safety and protection of the clinical trial participants from any immediate hazard to their health and safety,
in which case the REC was informed immediately by telephone and in writing within 3 days.
Annual progress reports to the REC included a listing of all related and unexpected SAEs. All SAEs were
reported to the Data Monitoring Committee (DMC) and Trial Steering Committee (TSC) on the occasion of
their meetings (i.e. every 6–12 months). The DMC viewed data with knowledge of treatment. In the event
of a participant dying as a result of the study protocol or study interventions, any postmortem findings
were to be provided to the chief investigator, who would report the findings to the DMC for continuous
safety review.
Data collection and quality assurance
The SALVO study met the requirements of the Data Protection Act 1998,65 NHS Caldicott principles,66 the
Research Governance Framework for Health and Social Care67 and REC approval. Identifiable information
collected from participants, including name, date of birth, hospital number and contact details, was
considered confidential and collected and stored only at the local NHS site. Study data were collected
using paper CRFs, with all data being pseudonymised using a unique participant number and transmitted
to the trials office by secure NHS e-mail transmission or post.
The following data were collected through CRFs.
l Before surgery: eligibility, obstetric history, indication for caesarean section, prognostic factors for
haemorrhage, demographics, due dates and labour data, preoperative haemoglobin and platelet count.
l During surgery: time of delivery, time into and out of theatre, transfusion of donor blood products,
set-up of cell salvage machine (if applicable), including consumables used and volume of blood
returned, reasons for no return of salvaged blood, documentation of any technical failure of cell
salvage, additional staff required in theatre owing to cell salvage.
l Between surgery and discharge: transfusion of donor blood products, postoperative haemoglobin,
FMH measured by Kleihauer test, anti-D administration, flow cytometry for Kleihauer results of > 2 ml,
repeat Kleihauer and anti-D administration for initial Kleihauer results of > 4 ml, time of mobilisation
and discharge, MFI, AEs including admission to higher level of care (HLC).
The CRF data were verified by the trials office and queries raised with individual sites for discrepancies
identified. Data were input at the trials office by delegated staff into a bespoke Oracle Database [11g Release 2
(Oracle Corporation, Redwood Shores, CA, USA)] with a Java [SE 7 (Oracle Corporation, Redwood Shores,
CA, USA)] user interface, set up and managed by the PCTU. Data quality was monitored through source data
verification on samples of patient records during on-site monitoring and during remote self-monitoring activities,
and through central statistical monitoring with discrepancies raised from database extracts, highlighting
outliers and discrepancies. On-site and self-monitoring activities also included verification of eligibility, informed
consent and completeness of local trial documents according to a predefined trial monitoring plan.
On 69 occasions, stratification factors were found to be entered incorrectly during the randomisation
procedure, but these were corrected to the true values in the analysis, which adjusted for stratification factors.
Additional quality control measures undertaken included a cross-check of primary outcome data against
local transfusion laboratory records on recommendation of the TSC. Manual data entry was also subject to
quality control procedures according to predefined procedures, with 100% of primary outcome data
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being checked and 10% of all other data being checked with an allowable error threshold of 2% for
non-primary outcome data.
Sample size
Establishing a baseline rate for the primary outcome was not straightforward because estimates in the
published literature for blood transfusion in caesarean section varied widely (1.8–23.5%).44,68 Factors
influencing this figure include country of origin, indication for caesarean section (emergency or elective) and
local transfusion policy. Our audits in two centres conducted at the time of study planning put transfusion
rates for an unselected caesarean section population at around 5%. A detailed audit of donor blood use at
the Royal Hallamshire Hospital Sheffield during the period 2009–10, without cell salvage in routine use, was
performed by cross-reference of perioperative records, blood bank data and electronic records stored in cell
salvage machines. It reported that in a recent series of 1647 caesarean sections over 10 months, 89 women
were transfused with donor blood, giving a rate of 5.4% (Ian Wrench, Royal Hallamshire Hospital Sheffield,
2011, personal communication). A similar audit at Birmingham Women’s Hospital of all caesarean sections
carried out in 2006 showed that, of 1674 women, 83 (5.0%) received a transfusion.43 Both auditing units
delivered approximately 7300 women per year with a comparable caesarean section rate and could thus be
considered representative of UK tertiary obstetric unit practice. Our pilot sample55 was too small to assist
in providing reliable information on sample size calculations. In the light of reported contemporary
observations and audited data on transfusion rates, the assumption of a 5% event rate was used to base
the main sample size calculation on.
The expected effect estimate was informed by the literature. Our systematic review43 and its most recent
update36 showed only one small trial, published in 1998,44 which randomised a total of 68 participants to
either cell salvage or standard care. The transfusion rate was 23.5% in the control group and 2.9% in
the cell salvage group. The control event rate was considerably higher than that observed in current UK
practice and inconsistent with literature from other sources.21,22 This was probably due to a sample at an
exceptionally high risk of haemorrhage. Weaknesses that raise the risk of bias (e.g. inadequate concealment
of randomisation) precluded reliance on it alone to inform our calculations. Non-obstetric literature
evaluating cell salvage in interventions with a moderate to high risk of transfusion had two high-quality
systematic reviews: a HTA report citing a RR of exposure to allogeneic blood of 0.59 (95% CI 0.48 to 0.73)
with salvage22 and a Cochrane review reporting a RR of 0.62 (95% CI 0.50 to 0.70) for transfusion with
salvage compared with normal practice.21 Detecting a smaller effect size would have been possible but the
larger sample size required had to be balanced against the cost and practicability of undertaking such a trial.
Based on the HTA report and Cochrane review cited,21,22 we assumed a relative risk for the intervention
effect of 0.6 (at a control event rate of 5%, the intervention group would have a transfusion rate of 3%).
Therefore, the planned sample size was a total of 3050 women (1525 per group), to detect an absolute
difference in the transfusion rate of 2% and given a power of 80% for a two-sided test, a type I error rate
of 5% and event rate of 5% in the control group. Our sample size allowed for primary outcome data and
follow-up loss of 1% of randomised cases.
The planned trial sample was also to represent an even split between elective and emergency caesarean
sections, the rationale for which was as follows: the primary event rate in the control group was based on
data representing caesarean section across ‘all-comers’ in obstetric units, including both emergencies and
elective cases. It included all indications at increased risk of haemorrhage. Ideally, this distribution would be
faithfully and proportionally represented in the trial population, but there was good reason to suspect that
clinicians would find it much more difficult or be more reluctant to recruit those patients at higher risk of
haemorrhage, such as emergency indications or in cases of placental abnormality. Equally, a decision to
limit recruitment to these high-risk groups alone, while desirable to maximise the primary outcome event
rate and reduce sample size, was likely to result in reluctance to take part in the study at all. Adoption of
such narrow eligibility criteria may have restricted sites from ever gaining a sufficient rate of recruitment to
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become confident in the trial processes and rendered the conduct of the trial unviable. In addition, at the
time the study was designed, there was an increasing trend for obstetric units to have started utilising cell
salvage in the routine, uncomplicated elective caesarean section population to facilitate the generation
of an effective skill base among clinical staff to support the deployment of the technology when deemed
necessary, even though the majority of these would not suffer significant blood loss. Therefore,
a pragmatic compromise to these conflicting requirements was to exclude those elective cases with the
very lowest risk of haemorrhage (elective first caesarean section for breech or maternal request) while at
the same time prespecifying a desired equal distribution across elective and emergency cases.
Between June 2013 and March 2014, the majority of the elective patient population was recruited relatively
rapidly, exceeding our projected target accrual. The emergency patient population was recruited more slowly,
along with high-risk elective cases (see Appendix 2, Figure 11). Although sites adapted to the more challenging
recruitment of these participants, particularly once the changes to the consenting procedures that were
introduced through a substantial protocol amendment had started to take effect, an extension of the projected
recruitment duration by 11 months was necessary to allow completion of the target sample size.
Interim analyses
There were no planned interim analyses for this trial. In the lead-up to the recruitment extension request,
the funding body recommended an interim futility analysis be presented to the unblinded DMC to assess
the probability of achieving a significant result, should the trial be allowed to recruit to completion. This
was performed in March 2015 but the DMC did not feel as though it was within its remit to make a
decision on the future of the trial based on said analysis. The DMC made its recommendation without the
use of the futility analysis results.
Randomisation
Randomisation to the allocated intervention (allocation ratio 1 : 1) was done using a bespoke web-based
randomisation system hosted by the University of Bristol. Randomisation of participants was done on the
delivery ward by local study staff. The randomisation used random permuted blocks of variable sizes to
ensure that trial staff conducting randomisation could not reliably predict the next allocation. Randomisation
was stratified by four criteria: centre, type of caesarean section (emergency vs. elective), presence of abnormal
placentation versus normal placentation and multiple pregnancy (twins or more) versus singleton pregnancy.
Blinding
Allocation concealment with third-party randomisation helped minimise selection bias. However, given the
nature of the intervention, it was not possible to blind local treatment staff and data entry staff to the
allocation. Performance bias may cause transfusion rates to vary. This risk was minimised by ensuring that
each centre had an intraoperative transfusion protocol for use in theatre and recovery to standardise
operative transfusion triggers across both study groups in each centre. Some centres adopted an agreed
haemoglobin threshold for transfusion, which was to be applied equally to both groups.
Sites were encouraged to blind postnatal carers to group allocation after caesarean section. The allocation
was not recorded in routine case notes, but this did not represent formal blinding as theatre notes were
available. The carers on postnatal wards were a different group of staff to the carers on labour wards and
operating theatres, and it was on the postnatal wards that the decisions for postoperative donor blood
transfusions were made, based on the postoperative haemoglobin level and maternal symptoms. In the
event of the need for a donor blood transfusion, serum haemoglobin was measured by blood sample, and
pre- and post-transfusion results recorded. This allowed monitoring of numeric transfusion thresholds
between units and groups. In the event that between-group variations in haemoglobin transfusion triggers
were indeed evident, consideration was given for adjusting for such differences in the final analysis.
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The study statistician remained blinded until completion of data collection and sign off of the statistical
analysis plan so as not to bias the analysis, and the chief investigator remained blinded until completion of
the analysis. For interim reporting purposes to the DMC during the running of the trial, an independent
statistician employed by the PCTU produced summaries of unblinded data for a closed report to the DMC.
Statistical methods
General considerations
A detailed analysis plan was developed and agreed by the TSC and the DMC prior to unblinding and data
analysis. All coding and analyses were performed using Stata® version 12 (StataCorp LP, College Station,
TX, USA). All analyses were intention to treat (ITT). When baseline covariates were missing, mean
imputation of the covariate in adjusted analyses were used (note that epidemiological arguments against
the use of a missing indicator do not apply in randomised trials).69 An ITT approach does not dictate that
all outcome data must have been collected,70 though pilot work for this trial suggested that all, or close to
all, of the primary outcome data would be obtained. When outcome data were missing, we analysed the
data for those who did have outcome data, adjusting for baseline covariates. This approach is unbiased if
missingness for the outcome is related to observed covariates (‘missing at random’). If missingness in the
primary outcome had been > 5% then a sensitivity analysis was to be conducted to explore the missing at
random assumption. In this case, a pattern/mixture model estimated by a mean score approach would
have been adopted.70
Post-randomisation exclusions
Although analysis was by ITT, certain exclusions were made post randomisation. These included all women
who were enrolled in error (e.g. who did not meet all eligibility criteria) or did not provide valid written
informed consent.
Women who withdrew their consent were still analysed unless they specified that their data were not to
be used, in which case the data were safely destroyed and excluded from the trial analysis. We also
excluded women who experienced a vaginal delivery, as this was not applicable to the outcomes analyses
in the sense of the trial, although their baseline characteristics remained available.
Post-randomisation exclusions were not replaced during the recruitment phase, as they were considered
part of the 1% anticipated loss to follow-up (see Sample size).
Evaluation of demographics, baseline covariates and implementation of intervention
Demographic factors and clinical characteristics were summarised with counts (percentages) for categorical
variables, mean with standard deviation (SD) for normally distributed continuous variables or median with
interquartile range (IQR) for other continuous variables. The number of participants who were eligible,
recruited and followed up were recorded in a CONSORT (Consolidated Standards of Reporting Trials) flow
chart. We also included summaries detailing implementation of the intervention, for example whether or
not swabs were washed.
Primary analysis
For the primary outcome measure of patient requirement of peripartum transfusion, differences in
treatment effect between treatment groups were assessed using logistic regression. Univariate and
multivariable logistic regression models were used to estimate crude and adjusted odds ratios (ORs) with
95% CIs. A two-sided p-value was reported in each case. The primary analysis was adjusted.
Adjusted analysis adjusts for a random effect of treatment centre and fixed effects of stratification variables
and other baseline characteristics believed to be associated with the outcome measure of haemorrhage.
The following are factors deemed to be associated antenatally with a substantial increase in the incidence of
PPH, according to RCOG guidelines:71 known placenta praevia and pre-eclampsia/gestational hypertension.
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Another factor believed to substantially increase risk of PPH is placental abruption.32,71 As the number of
individuals observed with this event was likely to be low, it was decided a priori that this covariate would
not be adjusted for in the primary analysis. Instead, the analysis was redone excluding those who
experienced placental abruption, as a sensitivity analysis.
Analysis of primary outcome: subgroup analysis
The following subgroup analyses were prespecified for the primary outcome:
l analysis of treatment effect by indication for caesarean section
l analysis of treatment effect by recruitment centre.
The first of these was analysed by statistically testing for an interaction term between treatment and
indication for caesarean section, and the second was analysed by testing for a random slope for the effect
of treatment at different treatment centres in addition to a random intercept.
Analysis of primary outcome: sensitivity analysis
The trial groups were compared according to this outcome on an ITT basis. However, because clinicians
managing women in the control group had access to a cell salvage machine, it was anticipated that
some women in the control group might receive cell salvage in place of a donor blood transfusion. As a
sensitivity analysis, we therefore analysed the primary outcome assuming that all instances of the return of
cell-salvaged blood in the control group would have been instances of donor blood transfusion had the
cell salvage machine not been present.
As mentioned above, the primary analysis was redone excluding those participants who experienced
placental abruption as an additional sensitivity analysis.
Analysis of other outcomes
Secondary outcome measures were compared between groups using appropriate methods. Linear
regression was used to analyse quantitative outcomes when a symmetric unimodal distribution is expected
(number of units transfused, postoperative serum haemoglobin, mean fall in serum haemoglobin level and
MFI scales). We analysed five scales of fatigue (each the total score of four items from the 20 statements
pertaining to a specific type of fatigue). The analysis of serum haemoglobin allowed for change from
baseline by including the preoperative level as an additional covariate.
Time to event variables (i.e. time to first mobilisation, length of hospital stay) were analysed with Cox
proportional hazard regression.
Fetomaternal haemorrhage was dichotomised into a Kleihauer test measurement of < 2 ml versus ≥ 2 ml
and analysed using logistic regression. Other measures detailing FMH, such as dose of anti-D prophylaxis
were summarised accordingly. In the analysis of FMH, we used a cut-off point of a Kleihauer result of
≥ 2 ml to dichotomise the measurement into a binary variable.63 However, owing to the phrasing of our
CRFs, certain measures, such as flow cytometry or repeat Kleihauer tests, were only taken in the event that
the initial Kleihauer test results were > 2 ml or > 4 ml, in accordance with guidelines.34 In addition, any
results reported as, for example, < 4 ml could not be dichotomised as described above and were therefore
classified as missing data.
Adverse events were analysed using logistic regression. Transfusion reaction associated with donor blood
transfusion was not analysed as we only saw one event.
Crude and adjusted estimates of treatment effect were obtained for each outcome, using univariate and
multivariable analyses with the same covariates as in the primary analysis.
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Further exploratory analyses
Further to the prespecified subgroup analyses, an analysis of treatment effect on donor blood transfusion
by abnormal placentation was undertaken for exploratory purposes. We also conducted further analysis to
test for consistency of treatment effect in secondary outcomes across subgroups of elective and emergency
caesarean section.
We conducted a further sensitivity analysis assuming that a donor blood transfusion would have been
required, had salvaged blood not been returned in the control when the cell salvage machine was set up
in an emergency situation only (as opposed to all cases of salvaged blood return in the control group).
We included this further analysis as an amendment to our original prespecified sensitivity analysis as we
recognised, with hindsight, that our assumptions about the erroneous return of salvaged blood in the
control group were broad. Therefore, we only reclassified cases for which the blood was returned in an
emergency as an attempt to more accurately reflect the truth.
There was also interest surrounding the effect of swab washing on the effectiveness of the intervention.
We compared transfusion rates between participants who did and did not have swabs washed, within
participants who had the cell salvage machine set up.
Governance and oversight
The SALVO trial was undertaken following clinical trials database registration (registry number
ISRCTN66118656) and the required regulatory approvals and local NHS permissions (UK REC North West –
Haydock, reference number 12/NW/0513). The study was funded by the National Institute for Health
Research (NIHR) as part of the HTA programme (reference number 10/57/32).
A trial management group (TMG) was responsible for the day-to-day running of the trial, with support
from the PCTU at Queen Mary University of London. The TMG reported to the TSC, which was composed
of an obstetrician, an independent statistician and a consumer representative, and which convened every
6–12 months and provided overall supervision of the trial. This included giving advice on trial protocol and
changes thereof, resolving problems brought to it by the TMG, monitoring the progress of the trial,
protocol adherence and patient safety, considering new information and recommendations of the DMC
and other authorities, and approving reports and papers for publication.
The DMC consisted of an independent statistician, obstetrician and anaesthetist. The DMC met
approximately every 12 months during the running of the trial and reviewed accruing trial data in order
to assess whether or not there were any ethics or safety issues as to why the trial should not continue.
Interim reports were supplied to the DMC in strict confidence and included unblinded data provided by a
PCTU statistician independent of the trial. The DMC formulated recommendations for the attention of the
TSC. Both committees also monitored the pooled primary outcome event rate (i.e. across both arms) and
formulated recommendations to encourage recruitment of the full spectrum of patients likely to benefit
from the intervention.
Patient and public involvement
Working with organised consumer groups capable of identifying research priorities and introducing their
ideas into research programmes was a crucial part of our activities leading to the trial. The National
Childbirth Trust (NCT) significantly strengthened the project, being well placed to reflect on their
experience in relation to avoiding the need for donor blood transfusion and to encourage participation.
A volunteer for the NCT collaborated with the project from its inception, advised on the pilot protocol
and agreed to provide representation on the TSC. An additional patient and public representative was
identified through ‘Katie’s Team’, the Queen Mary University of London women’s health research advisory
METHODS
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group, and included in the project at a later stage. This representative participated in TSC and clinical
investigator group meetings, reviewed the plain English summary for this report, and advised on
dissemination strategies.
In preparation for the trial, a survey was conducted among women who received cell salvage, showing
that they perceived the intervention as reassuring, safe and preferable to donor blood transfusion
(our primary outcome).
Summary of changes to the project protocol
No changes were made to the objectives, outcomes, eligibility criteria, sample size or statistical parameters
during the course of the trial. Three substantial and four minor amendments to the protocol were
implemented during the trial, which concerned changes to recruitment materials and strategies, clarifications
and administrative changes to the protocol, and an extension of the overall recruitment period.
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Chapter 3 Results
Participants
Between June 2013 and April 2016, 3054 participants requiring caesarean section from 26 participating
hospitals were recruited (Figure 2). Of these, 26 participants had to be excluded owing to issues
surrounding consent or eligibility, as follows.
l Nine participants gave verbal consent as per protocol (PP), but written consent could not be
obtained postoperatively.
l Four participants gave written informed consent, but the consent form was destroyed or missing and
consent could not be reobtained.
l Four participants had not given consent and were randomised in error, but were not exposed to any
trial intervention.
l One participant was found to have given invalid consent owing to language issues.
l One participant gave verbal consent but withdrew consent after surgery.
l Seven participants were found not to have met the eligibility criteria.
Therefore, 1517 participants were assigned to cell salvage (intervention) and 1511 to usual care (control).
Pregnancies resulting in vaginal delivery after assignment (n = 17 in the cell salvage group and n = 18 in
the control group) were excluded from the analysis, as were patients who were transferred to a different
hospital prior to delivery (n = 2 in the cell salvage group and n = 1 in the control group) and who were
Initially randomised
(n = 3054)
Exclusions
• Eligibility criteria not met, n = 7
• No written consent available, n = 18
• Withdrawn and specified that data should
   not be used, n = 1
Control group: analysed
(n = 1492)
Intervention group: analysed
(n = 1498)
Allocated to control
(n = 1511)
Allocation
Allocated to cell salvage
(n = 1517)
Follow-up
Analysis
• Excluded from analysis: vaginal delivery, 
   n = 18
• Lost to follow-up: moved centre prior to
   delivery, n = 1
• Received allocated intervention, n = 1434
• Did not receive allocated intervention, n = 58
• Excluded from analysis: vaginal delivery,
   n = 17 
• Lost to follow-up: moved centre prior to
   delivery, n = 2
• Received allocated intervention, n = 1432
• Did not receive allocated intervention, n = 66
FIGURE 2 Participant enrolment and follow-up. Reproduced from © 2017 Khan et al.72 This is an open access article
distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original author and source are credited.
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therefore lost to follow-up. However, the baseline characteristics for these 38 patients are included in the
tables of baseline characteristics. For the analysis, this left 2990 participants (n = 1498 in the cell salvage
and n = 1492 in the control group, respectively).
Baseline data
The main characteristics of participants were similar at baseline (Table 1). The distribution of participants
across the different sites is summarised in Table 2.
Implementation of cell salvage
In the intervention group, 1432 (95.6%) participants received their allocated treatment with the cell salvage
machine set up. There were 24 cases (1.6%) for which the cell salvage machine was unavailable or out of
order and 42 cases (2.8%) for which the machine was simply not set up in deviation of the protocol. In the
group receiving salvage, 50.8% had salvaged blood returned averaging 259.9 ml (Table 3). In the control
group, 1434 (96.1%) participants received their assigned intervention without the cell salvage machine set
up. In 15 cases (1.0%) the cell salvage machine was used in an emergency and in 43 cases (2.9%) it was set
up from the start of the operation, in deviation from the protocol.
Primary outcome
Overall, the donor blood transfusion rate was 2.5% in the group assigned to cell salvage and 3.5% in the
control group, but this result did not reach statistical significance [adjusted OR 0.65, 95% CI 0.42 to 1.01;
p = 0.056 (Table 4)]. In a subgroup analysis exploring the consistency of treatment effects in procedures
undertaken at different levels of urgency, the transfusion rate was 3.0% in women assigned to salvage
and 4.6% in the control group among emergency caesareans (adjusted OR 0.58, 95% CI 0.34 to 0.99),
whereas it was 1.8% in the intervention group and 2.2% in the control group among elective caesareans
(adjusted OR 0.83, 95% CI 0.38 to 1.83), but the interaction was not statistically significant (p = 0.46,
see Table 4).
There was no significant difference in the clinical effectiveness of the intervention between centres (p-value
for random slope = 0.091). In a prespecified sensitivity analysis assuming that a donor blood transfusion
would have been required, had salvaged blood not been returned in the control group (n = 31), the effect
of cell salvage was significant [5.6% vs. 2.5%, adjusted OR 0.39, 95% CI 0.26 to 0.59; p < 0.001 (see
Table 4)]. When excluding cases of placental abruption from the primary analysis, little difference in the
results was seen, with one transfusion excluded in the control group as a result [3.4% vs. 2.5%, adjusted
OR 0.67, 95% CI 0.43 to 1.03; p = 0.071 (see Table 4)].
We also reviewed primary outcome events against available transfusion guidelines in order to determine
whether or not the lack of blinding introduced bias. When specific haemoglobin thresholds were defined
in local guidelines, we compared these with participants’ reported postoperative haemoglobin values.
We found 25 instances (cell salvage group n = 14, control group n = 11) in which donor blood was
administered postoperatively without locally defined haemoglobin thresholds having been reached. The
TMG did not deem the difference between intervention groups a cause for concern, also accounting for
the fact that other less quantifiable factors may also be taken into account when deciding on donor blood
transfusion. Therefore, we did not adjust our analysis accordingly.
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TABLE 1 Characteristics of participants at baseline
Characteristics Control (N= 1511)a Cell salvage (N= 1517)a
Age at randomisation (years) 31.8 (5.8) 31.6 (5.7)
Preoperative haemoglobin (g/l)b 118.1 (11.5) [19] 118.4 (11.3) [11]
Type of caesarean
Elective 687 (45.5) 669 (44.1)
Emergency 824 (54.5) 848 (55.9)
Multiple births
Singleton 1428 (94.5) 1428 (94.1)
Twins or multiple 83 (5.5) 89 (5.9)
Placentation
Abnormalc 135 (8.9) 136 (9.0)
Normal 1376 (91.1) 1381 (91.0)
Placenta praevia 130 (8.6) 133 (8.8)
Placenta accreta 8 (0.5) 4 (0.3)
Pre-eclampsia 74 (4.9) 69 (4.5)
Previous emergency caesarean 602 (39.8) 633 (41.7)
Previous elective caesarean 241 (15.9) 231 (15.2)
Placental abruption 3 (0.2) 2 (0.1)
Ethnicity
White 1213 (80.3) 1219 (80.4)
Mixed 23 (1.5) 14 (0.9)
Asian or Asian British 158 (10.5) 173 (11.4)
Black or Black British 67 (4.4) 71 (4.7)
Other 50 (3.3) 40 (2.6)
Parity
0 571 (37.8) 583 (38.4)
1 556 (36.8) 562 (37.0)
2 240 (15.9) 238 (15.7)
≥ 3 144 (9.5) 134 (8.8)
Gravidity
1 420 (27.8) 441 (29.1)
2 467 (30.9) 465 (30.6)
≥ 3 624 (41.3) 611 (40.3)
a Denominator includes 38 patients lost to follow-up owing to vaginal delivery or transfer.
b Haemoglobin < 105 g/l: control group n= 159 (10.7%), cell salvage group n= 150 (10.0%).
c Placenta praevia and/or placenta accreta.
Data presented are n (%) or mean (SD) [n missing].
Adapted from © 2017 Khan et al.72 This is an open access article distributed under the terms of the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original
author and source are credited.
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Secondary outcomes
Allocation to cell salvage did not have an effect on the units of donor blood transfused [adjusted mean
difference (MD) –0.12, 95% CI –0.80 to 0.57; p = 0.74 (Table 5)].
A small difference was detected between cell salvage and control groups for time to mobilisation [median 0.74
days vs. 0.72 days, adjusted hazard ratio (HR) 1.11 days, 95% CI 1.03 to 1.19 days; p= 0.006 (see Table 5)].
This represented a shorter absolute median time to mobilisation of 0.02 days, that is, approximately half an
hour. A small difference was also observed in length of hospital stay [median 2.131 days vs. 2.126 days,
adjusted HR 1.08 days, 95% CI 1.00 to 1.16 days; p= 0.050 (see Table 5)]. This represented a shorter absolute
median hospital stay by 0.005 days, that is, approximately 10 minutes.
TABLE 2 Participants recruited per site
Centre Control (N= 1511)a Cell salvage (N= 1517)a
Birmingham Heartlands Hospital 41 (2.7) 44 (2.9)
Birmingham Women’s Hospital 7 (0.5) 6 (0.4)
Croydon University Hospital 48 (3.2) 48 (3.2)
Derriford Hospital Plymouth 57 (3.8) 59 (3.9)
Hinchingbrooke Hospital 83 (5.5) 84 (5.5)
James Cook University Hospital 109 (7.2) 108 (7.1)
Leicester General Hospital 5 (0.3) 4 (0.3)
Leicester Royal Infirmary 78 (5.2) 75 (4.9)
Norfolk and Norwich University Hospital 5 (0.3) 5 (0.3)
Northwick Park Hospital 13 (0.9) 15 (1.0)
Nottingham City Hospital 15 (1.0) 16 (1.0)
Queens Hospital Romford 60 (4.0) 58 (3.8)
Queens Medical Centre Nottingham 15 (1.0) 13 (0.9)
Royal Hallamshire Hospital Sheffield 138 (9.1) 139 (9.2)
Royal London Hospital 84 (5.6) 87 (5.7)
Royal Stoke University Hospital, Stoke-on-Trent 72 (4.8) 73 (4.8)
Royal United Hospital Bath 88 (5.8) 87 (5.7)
Royal Victoria Infirmary Newcastle 119 (7.9) 116 (7.7)
Simpson Centre Edinburgh 47 (3.1) 51 (3.4)
Singleton Hospital Swansea 84 (5.6) 88 (5.8)
St. Michaels Hospital Bristol 26 (1.7) 21 (1.4)
Sunderland Royal Hospital 192 (12.7) 190 (12.5)
Torbay Hospital 28 (1.9) 30 (2.0)
West Middlesex University Hospital 49 (3.2) 52 (3.4)
Whipps Cross University Hospital 29 (1.9) 27 (1.8)
Whiston Hospital 19 (1.3) 21 (1.4)
a Denominator includes 38 patients lost to follow-up owing to vaginal delivery or transfer.
Data presented are n (%).
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Analysis of postoperative haemoglobin levels showed no difference between cell salvage and control groups
[adjusted MD 0.63, 95% CI –0.09 to 1.35; p = 0.085 (see Table 5)] and this was also the case for fall in
haemoglobin level from baseline [adjusted MD –0.68, 95% CI –1.40 to 0.04; p = 0.066 (see Table 5)].
Among RhD-negative women giving birth to RhD-positive babies, allocation to cell salvage was associated
with greater FMH, defined as a Kleihauer testing result of ≥ 2 ml [10.5% vs. 25.6%, adjusted OR 5.63,
95% CI 1.43 to 22.14; p = 0.013 (see Table 5)]. It should be noted that for 67 patients, Kleihauer testing
was done but results could not be classified as they were reported as ‘< 4 ml’ or similar estimations,
according to local guidelines; these results are therefore not available for analysis. Anti-D was routinely
administered in the vast majority of RhD-negative mothers with RhD-positive babies (99.2% cases in
control group, 98.6% cases in cell salvage group) (Table 6), although a total of three women across both
TABLE 3 Detail of cell salvage use
Measure Control (N= 1492) Cell salvage (N= 1498)
Cell salvage machine set up
Set up 43 (2.9%) 1432 (95.6%)
Emergency use 15 (1.0%) 0 (0.0%)
Not set up 1434 (96.1%) 42 (2.8%)
Unavailable/out of order 0 (0.0%) 24 (1.6%)
Received allocated treatment 1434 (96.1%) 1432 (95.6%)
If cell salvage set up (including emergency use) (n = 1490)
Suckers used
1 27 (48.2%) 829 (58.1%)
2 29 (51.8%) 598 (41.9%)
Missinga 2 5
Swabs washed 21 (36.8%) [1] 781 (54.8%) [6]
Size of centrifuge bowl used (ml)b 183.2 (59.2) [2] 177.1 (59.8) [37]
LDF used 25 (43.9%) [1] 782 (54.9%) [7]
Salvaged blood returned 35 (60.3%) [0] 726 (50.8%) [3]
If blood returned during cell salvage (n = 761)
Volume of blood returned to mother (ml) 288.4 (198.3) 259.9 (149.7)
If no blood returned during cell salvage (n = 726)
Reason for no return
No blood produced 14 (63.6%) 575 (88.9%)
Technical error 0 (0.0%) 25 (3.9%)
Otherc 8 (36.4%) 47 (7.3%)
Missing 1 56
a Missing observations are not included in percentage calculations. When variables are categorical, missing values are
listed in a separate row, but are similarly not included in percentage calculations.
b Measure not applicable for sites with a continuous transfusion machine only (control group n= 22, cell salvage
group n= 180).
c Other reasons include ‘clinical decision’ (n= 7), ‘human error’ (n= 5), ‘meconium, infection risk or contamination’
(n= 12), ‘minimal processed blood’ (n= 25), ‘patient declined’ (n= 2), ‘tubing trapped next to centrifuge bowl’ (n= 1)
and ‘unclear’ (n= 3).
Data presented are n (%) or mean (SD) [n missing].
Reproduced from © 2017 Khan et al.72 This is an open access article distributed under the terms of the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original
author and source are credited.
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TABLE 4 Effect of intervention on donor blood transfusion
Analysis
Control
(N= 1492),
n (%)
Cell salvage
(N= 1498),
n (%)
Crude risk
difference %
(95% CI)
Crude
intervention OR
(95% CI)
p-value:
crude
analysis
Adjusteda
intervention OR
(95% CI)
p-value:
adjusted
analysis
Primary analysis
Overall 52 (3.5) 37 (2.5) –1.0 (–2.2 to 0.2) 0.70 (0.46 to 1.08) 0.10 0.65 (0.42 to 1.01) 0.056
Subgroup analysis
Emergency caesarean (n = 1641) 37 (4.6) 25 (3.0) 0.58 (0.34 to 0.99)
Elective caesarean (n= 1349) 15 (2.2) 12 (1.8) 0.83 (0.38 to 1.83)
p-value for interaction 0.46
Sensitivity analysis
Assumption: return of cell-salvaged blood in the control
group avoided transfusions
83 (5.6) 37 (2.5) –3.1 (–4.5 to –1.7) 0.43 (0.29 to 0.64) < 0.001 0.39 (0.26 to 0.59) < 0.001
Excluding participants with placental abruption (cell salvage
group: n= 2, control group: n = 3)
51 (3.4) 37 (2.5) –1.0 (–2.2 to 0.3) 0.72 (0.47 to 1.10) 0.13 0.67 (0.43 to 1.03) 0.071
a Adjusted for stratification factors [elective vs. emergency caesarean section, presence of abnormal placentation, singleton vs. twins or multiple births, recruitment centre (as a random
effect)] and other factors believed to be prognostic a priori (known placenta praevia, pre-eclampsia).
Adapted from © 2017 Khan et al.72 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original author and source are credited.
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TABLE 5 Analysis of secondary outcomes
Secondary outcomes
Control
(n= 1492)
Cell salvage
(n= 1498)
Crude intervention
OR/MD/HR (95% CI)
p-value:
crude
analysis
Adjusteda intervention
OR/MD/HR (95% CI)
p-value:
adjusted
analysis
Units of blood transfused,b mean (SD) 2.65 (1.66) 2.70 (1.70) 0.05 (–0.67 to 0.76) 0.89 –0.12 (–0.80 to 0.57) 0.74
Time to mobilisation (days),c,d median (IQR) [n missing] 0.74 (0.45) [49] 0.72 (0.45) [61] 1.07 (0.99 to 1.15) 0.079 1.11 (1.03 to 1.19) 0.006
Length of hospital stay (days),c,e median (IQR) [n missing] 2.13 (1.41) [24] 2.13 (1.37) [12] 1.04 (0.97 to 1.12) 0.26 1.08 (1.00 to 1.16) 0.050
Safety outcomes
Postoperative haemoglobin level (g/l),f mean (SD) [n missing] 103.1 (12.1) [47] 103.8 (12.2) [61] 0.74 (–0.15 to 1.63) 0.10 0.63 (–0.09 to 1.35) 0.085
Fall in haemoglobin level (g/l),f mean (SD) [n missing] 15.0 (11.2) [65] 14.5 (11.1) [72] –0.49 (–1.31 to 0.33) 0.24 –0.68 (–1.40 to 0.04) 0.066
Any AE experienced, n (%) [n missing
g
] 191 (12.8) [0] 199 (13.3) [1] 1.04 (0.84 to 1.29) 0.69 1.02 (0.81 to 1.29) 0.84
FMH,h n (%) [n missing] 9 (10.5) [33] 21 (25.6) [51] 2.95 (1.26 to 6.89) 0.013 5.63 (1.43 to 22.14) 0.013
a Adjusted for stratification factors [elective vs. emergency caesarean section, presence of abnormal placentation, singleton vs. twins or multiple births, recruitment centre (as a random
effect)] and other factors believed to be prognostic a priori (known placenta praevia, pre-eclampsia).
b Analysis within the subgroup of participants who received donor blood.
c Taken from time of delivery.
d Test of proportional hazards assumption crude analysis, p= 0.67; adjusted analysis, p= 0.18.
e Test of proportional hazards assumption crude analysis, p= 0.57; adjusted analysis, p= 0.39.
f Adjusted analysis also adjusts for preoperative measurement, as well as time postoperative measurement was taken after delivery (log-transformed) with mean imputation of missing
values for both covariates. Note that the decision to adjust for the latter was made by blinded members of the trial team after the signing off of the statistical analysis plan. Postoperative
haemoglobin of < 105 (g/l): control group, n= 787 (54.5%); cell salvage group, n= 750 (52.2%).
g Missing observations are not included in percentage calculations.
h Measured by Kleihauer test and dichotomised into a result of < 2 ml vs. ≥ 2ml. Analysis within the subgroup of participants who underwent a Kleihauer test. Measure set to missing
when results are not categorisable (e.g. Kleihauer result reported as < 4 ml): control group, n = 25; cell salvage group, n= 42.
Note
Analysis of transfusion reaction associated with allogeneic donor blood omitted owing to observing only one event (control group).
Adapted from © 2017 Khan et al.72 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original author and source are credited.
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groups did not seem to have received a minimum standard dose of anti-D following delivery, with a risk of
RhD alloimmunisation. The dose of anti-D that was administered is summarised in Table 6, with further
detail on management of large FMH detailed in Table 7. Out of the 140 RhD-negative mothers in the cell
salvage group, only 40.6% received a dose of 1500 IU, with 56.5% receiving 500 IU. It is worth nothing
that the updated guidance34 recommending a higher standard anti-D dose of 1500 IU after cell salvage
was published in 2014; therefore, practice in some centres with doses of 500 IU may predate publication
of these guidelines.
Kleihauer tests were undertaken on the majority of RhD-negative participants in both groups (92.2% cases
in the control group and 95.0% cases in the cell salvage group, see Table 6). A total of 5% of women
in cell salvage group and 7.8% women in the control group did not have Kleihauer tests undertaken
following delivery. It should be noted that a dose of 500 IU of anti-D covers a FMH of 4 ml and, although a
1500-IU anti-D dose covers a FMH of ≈12 ml, a small proportion of women may have had an even higher
fetomaternal bleed. A Kleihauer test is therefore recommended to determine if additional doses of anti-D
are needed in addition to the standard dose.
Repeat Kleihauer tests were undertaken 72 hours post anti-D administration for the majority of applicable
participants and further anti-D was administered for two participants (see Table 6). Overall, eight women
TABLE 6 Results concerning maternal RhD status
Measure Control (N= 1492) Cell salvage (N= 1498)
RhD-negative mother with RhD-positive baby, n (%) 130 (8.7) 140 (9.3)
If mother negative and baby positive, n (%) (N = 270)
Anti-D prophylaxis administered? n (%) 129 (99.2) 138 (98.6)
Anti-D prophylaxis dose (IU), n (%)
500 59 (46.1) 78 (56.5)
1500 67 (52.3) 56 (40.6)
Othera 2 (1.6) 4 (2.9)
Missingb 1 0
Kleihauer test performed? n (%) [n missing] 119 (92.2) [1] 133 (95.0) [0]
FMH (Kleihauer test result of ≥ 2ml) n (%) [n missing]c 9 (10.5) [33] 21 (25.6) [51]
Sample sent for flow cytometry, n (%)d 1 (33.3) 9 (75.0)
Repeat Kleihauer test performed? n (%)e 1 (50.0) 6 (100.0)
Further anti-D prophylaxis administered? n (%) [n missing]e 1 (100.0) [1] 1 (16.7) [0]
Further anti-D prophylaxis dose (IU), n (%)
250 0 (0.0) 1 (100.0)
1500 1 (100.0) 0 (0.0)
a Other doses include, for the control group, 1250 IU, 4000 IU, and, for the cell salvage group, 1000 IU, 1000 IU, 4500 IU,
5000 IU. See Table 7 for details.
b Missing observations are not included in percentage calculations. When variables are categorical, missing values are
listed in a separate row, but are similarly not included in percentage calculations.
c Measure set to missing when results are not categorisable [e.g. Kleihauer result reported as < 4ml (control group,
n= 25; cell salvage group, n= 42)].
d Measure only collected for participants with Kleihauer test result of > 2ml (control group, n= 3; cell salvage
group, n= 12).
e Measure only collected for participants with Kleihauer test result of > 4ml (control group, n= 2; cell salvage group, n= 6).
Occurrences of Kleihauer test results of > 4ml are in control group > 4ml,= 37ml, and cell salvage group= 5ml,= 6ml,
= 6ml,= 10ml,= 11ml,= 26ml. See Table 7 for details.
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(n = 2 in the control group and n = 6 in the intervention group) had larger instances of FMH with a
Kleihauer test result of > 4 ml. Of the two in the control group, one woman had the largest observed FMH
on the study, with 37 ml. She was managed as per guidelines with flow cytometry for confirmation of the
FMH volume, additional anti-D dose administered and a repeat Kleihauer test undertaken. The other had
an initial Kleihauer test result of > 4 ml and so was administered 1500 IU of anti-D but had no flow
cytometry undertaken. Neither of these two women in the control group received cell salvage. Out of the
six women in the intervention group, five had received cell-salvaged blood back. All six women had
confirmatory flow cytometry done and repeat Kleihauer tests undertaken.
TABLE 7 Management of RhD-negative women with FMH of ≥ 2ml by Kleihauer test
FMH by
Kleihauer (ml)
Anti-D dose
(IU)
Flow cytometry
undertakena
Flow cytometry
result (ml)
Repeat Kleihauer
undertakenb
Blood returned
during cell salvage?
Cell salvage group (n= 21)
26 4500 Yes 26 Yes Yes
11 1500 Yes 9 Yes Yes
10 1500 Yes 10 Yes Yes
6 1000 Yes 5 Yes No
6 1000 Yes 6 Yes Yes
5 1500 Yes 12 Yesc Yes
4 5000 No – – No
4 500 Yes 2 – No
3 500 No – – Yes
3 None No – – No
> 2 500 Yes 2 – Yes
> 2 1500 Yes 7 – Yes
2 1500 – – – Yes
2 1500 – – – No
2 1500 – – – Yes
2 500 – – – Yes
2 500 – – – Yes
2 500 – – – Yes
2 500 – – – Yes
2 500 – – – Yes
2 500 – – – No
Control group (n= 9)
37 4000 Yes 37 Yesc Not set up
> 4 1500 No – No Not set up
3 500 No – – Not set up
2 500 – – – Not set up
2 (5 patients) 1500 – – – Not set up
a Flow cytometry data were only collected for Kleihauer test result of > 2 ml.
b Repeat Kleihauer data were only collected for Kleihauer test result of > 4 ml.
c Repeat anti-D also administered.
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Breakdowns of FMH by sucker use and return of salvaged blood were also summarised (Table 8). On a
descriptive level, sucker use appeared to have little effect on the proportion of participants experiencing
FMH (28.3% when one sucker was used vs. 25.0% when two suckers were used). Return of salvaged
blood appeared to increase FMH (13.0% in cases of no salvaged blood returned vs. 48.4% in cases for
which salvaged blood was returned).
Administration of other donor products (namely fresh-frozen plasma, platelets and cryoprecipitate) is
summarised in Table 9.
TABLE 8 Fetomaternal haemorrhage by sucker use and by return of salvaged blood
One sucker used (N= 53) Two suckers used (N= 24)
FMHa 15 (28.3) 6 (25.0)
No blood returned (N= 46) Blood returned (N= 31)
FMHb 6 (13.0) 15 (48.4)
a Measured by Kleihauer test and dichotomised into a result of < 2ml vs. ≥ 2 ml. Summaries within participants who had
the cell salvage machine set up (including emergency use), for those with complete data on FMH and sucker use.
b Summaries within participants who had the cell salvage machine set up (including emergency use), for those with
complete data on FMH and return of blood during cell salvage.
Data presented are n (%).
TABLE 9 Detail of administration of donor products
Measure Control (N= 1492) Cell salvage (N= 1498)
Intraoperative
Donor blood given, n (%) 20 (1.3) 12 (0.8)
Unitsa of blood, mean (SD) 2.60 (1.27) 2.08 (0.51)
FFP given, n (%) 9 (0.6) 3 (0.2)
Units of FFP, mean (SD) 2.11 (0.33) 3.00 (1.00)
Platelets given, n (%) 2 (0.1) 0 (0.0)
Units of platelets, mean (SD) 1.50 (0.71) –
Cryoprecipitate given, n (%) 2 (0.1) 0 (0.0)
Units of cryoprecipitate, mean (SD) 2.00 (0.00) –
Postnatal
Donor blood given, n (%) 36 (2.4) 30 (2.0)
Units of blood, mean (SD) 2.39 (1.57) 2.50 (1.68)
FFP given, n (%) 8 (0.5) 7 (0.5)
Units of FFP, mean (SD) 3.25 (2.19) 3.29 (0.95)
Platelets given, n (%) 2 (0.1) 1 (0.1)
Units of platelets, mean (SD) 1.00 (0.00) 1.00 (–)
Cryoprecipitate given, n (%) 3 (0.2) 0 (0.0)
Units of cryoprecipitate, mean (SD) 2.00 (0.00) –
FFP, fresh-frozen plasma.
a Unit summaries considered within participants who received the specified blood product.
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The MFI questionnaire was completed for 2408 (80.5%) participants. Analysis of MFI statement scores
showed no significant differences between allocation groups for the fatigue categories of ‘general fatigue’,
‘physical fatigue’, ‘reduced motivation’ or ‘reduced activity’. There was a modest difference between the
cell salvage and control groups for ‘mental fatigue’ [adjusted MD –0.30, 95% CI –0.59 to –0.01; p = 0.043
(Table 10)].
As for process outcomes, the cell salvage machine was set up for 1490 participants across both groups
and salvaged blood was processed and returned for a total of 761 participants [35 out of 58 (60.3%) in
the control group and 726 out of 1432 (50.8%) in the cell salvage group]. Volume of salvaged blood was
recorded and summarised and reasoning behind no return of salvaged blood was also denoted, with the most
common reason being that no blood was produced by the cell salvage machine. Further measures detailing
implementation of the intervention, such as machine settings and equipment use, are summarised in Table 11.
Adverse events
There were 453 AEs reported in total across both groups, with 191 participants experiencing 220 AEs in
total in the control group and 199 participants experiencing a total of 233 AEs in the cell salvage group.
There was no significant difference between allocation groups for experiencing an AE (adjusted OR 1.02,
95% CI 0.81 to 1.29; p = 0.84, see Table 5). Table 12 shows details and descriptions of AEs. One case of
transfusion reaction associated with allogeneic donor blood was observed in the control group. There was
no case of AFE observed, with or without use of a LDF.
In 18 cases, AEs were considered to be related to cell salvage, with 15 events possibly related, two events
probably related and one event definitely related to the intervention. Table 13 shows details of related AEs.
Of the 18 AEs classed as related to cell salvage, the majority (n = 16) were also in the context of the use of
a LDF. These included transient episodes of hypotension that might have been related to the return of
cell-salvaged blood, as well as haemorrhagic and infective complications. As cell salvage removes clotting
factors and platelets, it can theoretically lead to coagulopathy unless coagulation products are simultaneously
given, and there is also a potential risk of returning infective agents such as bacteria in the salvaged blood.
The ultimate judgement on whether or not these complications might have been caused by cell salvage lay
with the local principal investigator.
TABLE 10 Analysis of MFI
MFI groupsa
Control
(n= 1187)
Cell salvage
(n= 1221)
Crude MD
(95% CI)
p-value:
crude
analysis
Adjusted(b) MD
(95% CI)
p-value:
adjusted
analysis
General fatigue 12.7 (3.6) [52] 12.5 (3.6) [39] –0.18 (–0.47 to 0.12) 0.24 –0.18 (–0.47 to 0.11) 0.22
Physical fatigue 12.3 (3.9) [22] 12.3 (3.9) [31] –0.05 (–0.36 to 0.26) 0.75 –0.06 (–0.37 to 0.25) 0.69
Reduced motivation 9.6 (3.3) [36] 9.8 (3.4) [46] 0.12 (–0.15 to 0.40) 0.37 0.13 (–0.14 to 0.40) 0.36
Reduced activity 11.3 (3.8) [42] 11.4 (3.6) [47] 0.12 (–0.18 to 0.43) 0.44 0.12 (–0.18 to 0.41) 0.45
Mental fatigue 8.7 (3.6) [19] 8.4 (3.6) [41] –0.28 (–0.57 to 0.01) 0.061 –0.30 (–0.59 to –0.01) 0.043
a Sum of MFI statement scores (when participants indicate agreement within a statement between 1 and 5) within fatigue
categories. Higher scores indicate increased fatigue.
b Adjusted for stratification factors [elective vs. emergency caesarean section, presence of abnormal placentation, singleton
vs. twins or multiple births, recruitment centre (as a random effect)] and other factors believed to be prognostic a priori
(known placenta praevia, pre-eclampsia).
Data presented are mean (SD) [n missing].
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TABLE 11 Other details regarding cell salvage use
Measure Control (N= 1492) Cell salvage (N= 1498)
If cell salvage set up (including emergency use) (n = 1490)
Collection sets useda
0 0 (0.0) 1 (0.1)
1 36 (100.0) 1240 (99.3)
2 0 (0.0) 7 (0.6)
3 0 (0.0) 1 (0.1)
Missingb 0 3
Processing packs useda
0 2 (5.7) 50 (4.0)
1 32 (91.4) 1179 (94.5)
2 1 (2.9) 13 (1.0)
3 0 (0.0) 4 (0.3)
4 0 (0.0) 2 (0.2)
Missing 1 4
Default settings used 54 (94.7) [1] 1287 (90.3) [6]
a Measure not applicable for sites with a continuous transfusion machine only (cell salvage group: n= 180, control
group: n= 22).
b Missing observations are not included in percentage calculations. When variables are categorical, missing values are
listed in a separate row, but are similarly not included in percentage calculations.
Data presented are n (%) [n missing].
TABLE 12 Detail of AEs
Measure Control (N= 1492) Cell salvage (N= 1498)
Any AE experienced 191 (12.8) [0] 199 (13.3) [1]
Total AEs 220 233
Breakdowns per AE (n = 453)
AE severity
Mild 89 (40.5) 101 (43.3)
Moderate 88 (40.0) 92 (39.5)
Severe 34 (15.4) 35 (15.0)
Life-threatening 9 (4.1) 4 (1.7)
Fatal 0 (0.0) 1 (0.4)
AE relatedness to intervention (if cell salvage set up, including emergency use) (n = 238)
Unrelated 8 (57.1) 160 (71.4)
Unlikely 5 (35.7) 47 (21.0)
Possiblea 1 (7.1) 14 (6.3)
Probablea 0 (0.0) 2 (0.9)
Definitea 0 (0.0) 1 (0.4)
Is the AE seriousb 20 (9.1) 15 (6.4)
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TABLE 12 Detail of AEs (continued )
Measure Control (N= 1492) Cell salvage (N= 1498)
AE descriptionsc by system organ class
Blood and lymphatic system disorders
Thrombocytopenia 0 (0.0) 3 (1.3)
Anaemia 2 (0.9) 6 (2.6)
Cardiac disorders
Sinus tachycardia 0 (0.0) 5 (2.2)
Hypotension 2 (0.9) 2 (0.9)
Supraventricular tachycardia 1 (0.5) 1 (0.4)
Gastrointestinal disorders
Diarrhoea 0 (0.0) 1 (0.4)
Ileus 4 (1.8) 3 (1.3)
Incontinence 0 (0.0) 1 (0.4)
General disorders and administration site conditions
Pain 4 (1.8) 3 (1.3)
Non-cardiac chest pain 1 (0.5) 0 (0.0)
Immune system disorders
Reaction to cell-salvaged blood 0 (0.0) 5 (2.2)
Reaction to donor blood 1 (0.5) 0 (0.0)
Allergic reaction 1 (0.5) 0 (0.0)
Infections and infestations
Lung infection 2 (0.9) 0 (0.0)
Wound infection 5 (2.3) 6 (2.6)
Uterine infection 1 (0.5) 2 (0.9)
Sepsis 11 (5.0) 11 (4.7)
Unknown source 12 (5.5) 21 (9.0)
Injury, poisoning and procedural complications
Wound dehiscence 1 (0.5) 2 (0.9)
Metabolism and nutrition disorders
Hyperglycaemia 0 (0.0) 1 (0.4)
Musculoskeletal and connective tissue disorders
Pain in extremity 0 (0.0) 2 (0.9)
Back pain 1 (0.5) 0 (0.0)
Nervous system disorders
Presyncope 2 (0.9) 3 (1.3)
Seizure 2 (0.9) 1 (0.4)
Limb weakness 0 (0.0) 1 (0.4)
continued
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TABLE 12 Detail of AEs (continued )
Measure Control (N= 1492) Cell salvage (N= 1498)
Pregnancy, puerperium and perinatal conditions – other
Hypertensive disease of pregnancy 32 (14.6) 34 (14.6)
Uterine atony 1 (0.5) 0 (0.0)
Placental abnormality 2 (0.9) 1 (0.4)
Maternal exposure to fetal blood 1 (0.5) 0 (0.0)
Renal and urinary disorders
Urinary retention 3 (1.4) 2 (0.9)
Oliguria 3 (1.4) 0 (0.0)
Chronic kidney disease 0 (0.0) 1 (0.4)
Prolonged catheterisation 1 (0.5) 3 (1.3)
Proteinuria 1 (0.5) 1 (0.4)
Haematuria 1 (0.5) 1 (0.4)
Reproductive system and breast disorders
Fibroids 1 (0.5) 0 (0.0)
Uterine haemorrhage 106 (48.4) 93 (39.9)
Respiratory, thoracic and mediastinal disorders
Cough 0 (0.0) 1 (0.4)
Dyspnoea 1 (0.5) 0 (0.0)
Hypoxia 1 (0.5) 1 (0.4)
Pulmonary oedema 0 (0.0) 1 (0.4)
Sleep apnoea 1 (0.5) 0 (0.0)
Skin and subcutaneous tissue disorders
Pruritus 0 (0.0) 1 (0.4)
Surgical and medical procedures: other
Anaesthetic complication 3 (1.4) 1 (0.4)
Surgical complication 5 (2.3) 2 (0.9)
Wound haematoma 1 (0.5) 5 (2.2)
Vascular disorders
Venous eczema 0 (0.0) 1 (0.4)
Hypertension 1 (0.5) 3 (1.3)
Thromboembolic event 1 (0.5) 1 (0.4)
Missingd 1 0
a For further detail see Table 13.
b For further detail see Table 14.
c Descriptions are coded by the trial team.
d Missing observations are not included in percentage calculations. When variables are categorical, missing values are
listed in a separate row, but are similarly not included in percentage calculations.
Data presented are n (%) [n missing].
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There were 36 SAEs reported during the SALVO trial. Of these, 32 are included in the AE table (Table 14),
with one SAE having three AEs pertaining to it. There were four additional SAEs concerning the offspring
(e.g. congenital anomalies), which did not require reporting for the main AE analysis. One fatal event was
observed among trial participants. It was considered unrelated to the intervention. This maternal death
occurred in a patient who died on the sixth day following her delivery.
TABLE 13 Further detail for events potentially related to cell salvage
AE relatedness
to intervention Allocation System organ class of AE AE description
Possible Control Reproductive system and breast disorders Uterine haemorrhage
Possible Cell salvage Cardiac disorders Hypotension
Possible Cell salvage Immune system disorders Reaction to cell-salvaged blood
Possible Cell salvage Immune system disorders Reaction to cell-salvaged blood
Possible Cell salvage Infections and infestations Sepsis
Possible Cell salvage Infections and infestations Unknown source
Possible Cell salvage Infections and infestations Unknown source
Possible Cell salvage Infections and infestations Unknown source
Possible Cell salvage Infections and infestations Unknown source
Possible Cell salvage Infections and infestations Unknown source
Possible Cell salvage Infections and infestations Unknown source
Possible Cell salvage Reproductive system and breast disorders Uterine haemorrhage
Possible Cell salvage Reproductive system and breast disorders Uterine haemorrhage
Possible Cell salvage Surgical and medical procedures – other Wound haematoma
Possible Cell salvage Infections and infestations Wound infection
Probable Cell salvage Immune system disorders Reaction to cell-salvaged blood
Probable Cell salvage Immune system disorders Reaction to cell-salvaged blood
Definite Cell salvage Immune system disorders Reaction to cell-salvaged blood
TABLE 14 Further detail for SAEs
Descriptiona of SAE Allocation Reason for seriousness
SAE relatedness
to intervention
Bladder damage during surgeryb Control Hospitalisation > 7 days Unrelated
Concealed obstetric haemorrhage Control Life-threatening Unrelated
HELLP syndrome Control Other Unrelated
Infection of unknown origin Control Hospitalisation > 7 days Unrelated
Massive obstetric haemorrhage Control Life-threatening Unrelated
Massive obstetric haemorrhage Control Life-threatening Unlikely
Massive obstetric haemorrhage Control Life-threatening Unrelated
Massive obstetric haemorrhage Control Life-threatening Unrelated
Massive obstetric haemorrhage Control Life-threatening Unrelated
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TABLE 14 Further detail for SAEs (continued )
Descriptiona of SAE Allocation Reason for seriousness
SAE relatedness
to intervention
Massive obstetric haemorrhage Control Life-threatening Unrelated
Massive obstetric haemorrhage Control Life-threatening Unrelated
Pneumonia Control Hospitalisation > 7 days Unrelated
Pre-eclampsia Control Hospitalisation > 7 days Unrelated
Pre-eclampsia Control Hospitalisation > 7 days Unrelated
Pulmonary embolism and obstetric
haemorrhage
Control Life-threatening Unrelated
Sepsis Control Hospitalisation > 7 days Unrelated
Vertebral disc prolapse Control Disability/incapacity Unlikely
Wound complication Control Hospitalisation > 7 days Unrelated
Bowel obstruction, caecal gangrene Cell salvage Hospitalisation > 7 days Unrelated
Bowel perforation, sepsis, multi-organ
failure
Cell salvage Fatal Unrelated
Fetal congenital abnormalityc Cell salvage Congenital abnormality/birth defect Unrelated
Fetal congenital abnormalityc Cell salvage Congenital abnormality/birth defect Unrelated
Fetal epidermolysis bullosac Cell salvage Congenital abnormality/birth defect Unrelated
Hypertension Cell salvage Hospitalisation > 7 days Unrelated
Massive obstetric haemorrhage Cell salvage Life-threatening Unlikely
Massive obstetric haemorrhage Cell salvage Life-threatening Unrelated
Palpitations and shortness of breath.
Postpartum echocardiogram suggested
mild left ventricular systolic dysfunction
Cell salvage Hospitalisation > 7 days Unlikely
Pre-eclampsia Cell salvage Hospitalisation > 7 days Unrelated
Pre-eclampsia Cell salvage Hospitalisation > 7 days Unrelated
Pre-existing atrial fibrillation and wound
complication
Cell salvage Hospitalisation > 7 days Unrelated
Reaction to salvaged blood or LDF
(hypotension)
Cell salvage Life-threatening Probably
Reaction to salvaged blood or LDF
(tachycardia, dyspnoea)
Cell salvage Life-threatening Definitely
Sepsis Cell salvage Hospitalisation > 7 days Unlikely
Sepsis Cell salvage Hospitalisation > 7 days Unlikely
Stillbirthc Cell salvage Congenital abnormality/birth defect Unrelated
Wound complication Cell salvage Hospitalisation > 7 days Unrelated
Wound complication Cell salvage Hospitalisation > 7 days Unrelated
HELLP, haemolysis, elevated liver enzymes, low platelet count.
a Descriptions are coded by the trial team.
b Participant had three AEs that were ticked as serious, all falling under the SAE described.
c SAEs not included in Table 12 as they concern the fetus, not the mother.
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Two serious adverse reactions were reported in this trial (i.e. SAEs that were considered related to the
intervention). The first was reported as a reaction to salvaged blood. The patient became tachycardic,
flushed and had difficulty breathing, starting shortly after the start of the retransfusion and resolving
completely once the transfusion was stopped. The event was classed by the local investigator as
life-threatening and as most likely due to the use of a LDF. The second event was a sudden onset of
hypotension, following retransfusion of 600 ml of cell-salvaged blood. The patient recovered fully.
The event was also reported as life-threatening and as most likely secondary to the use of a LDF.
Further exploratory analyses
There was no significant difference in the clinical effectiveness of cell salvage on secondary outcomes
between elective and emergency caesarean section (Table 15) or in the effect of cell salvage on reducing
donor blood transfusion between participants with normal and abnormal placentation (p-value for
interaction term = 0.28, Table 16).
In a sensitivity analysis assuming that a donor blood transfusion would have been required had salvaged
blood not been returned in the control when the cell salvage machine was set up in an emergency (n = 8),
the effect of cell salvage on donor blood transfusion was significant [4.0% vs. 2.5%, adjusted OR 0.56,
95% CI 0.36 to 0.86; p = 0.008 (Table 17)].
We observed that swab washing greatly increased the proportion of participants who received salvaged
blood (16.0% when swabs were not washed vs. 81.3% when swabs were washed) and that the volume
of blood returned was higher when swabs were washed [mean (SD) = 32.8 (100.5) when swabs were not
washed vs. 219.3 (169.8) when swabs were washed] (Table 18). In a comparison between participants
who did and did not have swabs washed within those who had the cell salvage machine set up, no
significant difference in the transfusion rates was observed [adjusted OR 0.79, 95% CI 0.39 to 1.57;
p = 0.50 (Table 19)].
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TABLE 15 Analysis of secondary outcomes: further exploratory subgroup analysis
Secondary outcome
Elective caesarean section (N= 1349) Emergency caesarean section (N= 1641)
p-value for
interaction
termControl (n= 684)
Cell salvage
(n= 665)
Adjusteda intervention
OR/MD/HR (95% CI) Control (n= 808)
Cell salvage
(n= 833)
Adjusted intervention
OR/MD/HR (95% CI)
Units of blood transfused,b
mean (SD)
3.33 (2.53) 2.92 (2.35) –0.20 (–1.42 to 1.02) 2.38 (1.06) 2.60 (1.32) –0.08 (–0.92 to 0.77) 0.87
Time to mobilisation (days),c
median (IQR) [n missing]
0.79 (0.43) [30] 0.79 (0.46) [29] 1.03 (0.92 to 1.15) 0.69 (0.45) [19] 0.66 (0.43) [32] 1.18 (1.07 to 1.30) 0.083
Length of hospital stay (days),c
median (IQR) [n missing]
2.10 (1.21) [19] 2.08 (1.00) [10] 1.06 (0.95 to 1.18) 2.20 (1.81) [5] 2.18 (1.49) [2] 1.09 (0.99 to 1.20) 0.70
Postoperative haemoglobin
level (g/l),d mean (SD)
[n missing]
104.28 (11.19) [17] 106.18 (12.05) [25] 1.19 (0.12 to 2.25) 102.03 (12.78) [30] 101.91 (12.03) [36] 0.17 (–0.80 to 1.14) 0.17
Fall in haemoglobin level (g/l),e
mean (SD) [n missing]
12.37 (9.41) [21] 11.66 (9.92) [27] –1.18 (–2.24 to -0.11) 17.32 (12.17) [44] 16.86 (11.53) [45] –0.26 (–1.23 to 0.72) 0.21
Any AE experienced, n (%)
[n missing]e
48 (7.0) [0] 48 (7.2) [0] 1.08 (0.70 to 1.66) 143 (17.7) [0] 151 (18.1) [1] 1.00 (0.77 to 1.31) 0.78
FMH,f n (%) [n missing] 4 (10.3) [13] 9 (26.5) [17] 9.71 (1.11 to 85.11) 5 (10.6) [20] 12 (25.0) [34] 4.08 (0.81 to 20.51) 0.51
a Adjusted for stratification factors [elective vs. emergency caesarean section, presence of abnormal placentation, singleton vs. twins or multiple births, recruitment centre (as a random
effect)] and other factors believed to be prognostic a priori (known placenta praevia, pre-eclampsia).
b Analysis within the subgroup of participants who received donor blood.
c Taken from time of delivery.
d Adjusted analysis also adjusts for preoperative measurement, as well as time postoperative measurement was taken after delivery (log-transformed) with mean imputation of missing
values for both covariates. Please note that the decision to adjust for the latter was made by blinded members of the trial team after the signing off of the statistical analysis plan.
e Missing observations are not included in percentage calculations.
f Measured by Kleihauer test and dichotomised into a result of < 2 vs. ≥ 2ml. Analysis within the subgroup of participants who underwent a Kleihauer test.
Note
Analysis of transfusion reaction associated with allogeneic donor blood omitted owing to observing only one event (control group).
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TABLE 17 Analysis of primary outcome: further exploratory sensitivity analysis
Event
Control
(N= 1492),
n (%)
Cell
salvage
(N= 1498),
n (%)
Crude risk
difference,
% (95% CI)
Crude
intervention
OR (95% CI)
p-value:
crude
analysis
Adjusted(a)
intervention
OR (95% CI)
p-value:
adjusted
analysis
Donor
blood
transfusion:
sensitivity
analysis 3b
60 (4.0) 37 (2.5) –1.6
(–2.8 to –0.3)
0.60
(0.40 to 0.92)
0.018 0.56
(0.36 to 0.86)
0.008
a Adjusted for stratification factors [elective vs. emergency caesarean section, presence of abnormal placentation, singleton
vs. twins or multiple births, recruitment centre (as a random effect)] and other factors believed to be prognostic a priori
(known placenta praevia, pre-eclampsia).
b Assuming all instances of blood returned using cell salvage set up in an emergency in the control group would have
been transfusions had the cell salvage machine not been present.
TABLE 18 Summaries specific to swab washing
Measure
Swab washing
Not washed (n= 681) Washed (n= 802)
Salvaged blood returned, n (%) [n missinga] 109 (16.0) [1] 651 (81.3) [1]
Volume of blood returned to mother (ml), mean (SD) 32.8 (100.5) 219.3 (169.8)
a Missing observations are not included in percentage calculations.
TABLE 16 Analysis of primary outcome: further exploratory subgroup analysis – placentation
Event
Placentation
p-value for
interaction
term
Normal (n= 2720) Abnormal (n= 270)
Control
(N= 1357),
n (%)
Cell
salvage
(N= 1363),
n (%)
Adjusteda
intervention
OR (95% CI)
Control
(N= 135),
n (%)
Cell
salvage
(N= 135),
n (%)
Adjusted
intervention
OR (95% CI)
Donor
blood
transfusion
40 (2.9) 24 (1.8) 0.56
(0.34 to 0.94)
12 (8.9) 13 (9.6) 0.98
(0.42 to 2.32)
0.28
a Adjusted for stratification factors [elective vs. emergency caesarean section, presence of abnormal placentation, singleton
vs. twins or multiple births, recruitment centre (as a random effect)] and other factors believed to be prognostic a priori
(known placenta praevia, pre-eclampsia).
TABLE 19 Analysis of primary outcome: further exploratory analysis by swab washing
Event
Swabs not washed
(N= 681), n (%)
Swabs washed
(N= 802), n (%)
Crude OR
(95% CI)
p-value:
crude
analysis
Adjusteda
OR (95% CI)
p-value:
adjusted
analysis
Donor blood
transfusionb
18 (2.6) 18 (2.2) 0.85
(0.44 to 1.64)
0.62 0.79
(0.39 to 1.57)
0.50
a Adjusted for stratification factors [elective vs. emergency caesarean section, presence of abnormal placentation, singleton
vs. twins or multiple births, recruitment centre (as a random effect)] and other factors believed to be prognostic a priori
(known placenta praevia, pre-eclampsia).
b Analysis within participants who had the cell salvage machine set up (including emergency use), for those with complete
swab washing data.
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Chapter 4 Health economic evaluation
Introduction
This chapter reports the economic evaluation carried out alongside the SALVO trial. The primary objective of
the study was to determine whether or not the routine use of cell salvage during caesarean section, in
women at risk of haemorrhage, reduced the need for donor blood transfusion compared with standard care.
Methods
To compare the costs and outcomes of cell salvage and standard care in the SALVO trial, a decision-analytic
model was deemed the most suitable method of presenting the alternative pathways and collating the data
for analysis and sensitivity analysis. In a decision-analytic model, consequences are expressed as probabilities,
weighted against costs and outcomes to derive an expected value for each alternative option.73 The
economic evaluation took the form of a cost-effectiveness analysis from the perspective of the health-care
provider based on the principal clinical outcome of the trial. The main comparison is the use of cell salvage
versus standard care. The results are reported in terms of the additional cost per donor blood transfusion
avoided by using cell salvage compared with standard care. Standard care is defined for the purposes of the
trial as ‘transfusion of donor blood according to standard local guidelines’. Costs were calculated in 2014–15
Great British pounds. Given the objectives of the trial and the duration of follow-up, only a within-trial
economic analysis was carried out and outcomes beyond this point were not considered relevant.
Model structure
A decision tree model was developed in TreeAge Pro 2016 (TreeAge Software, Inc., Williamstown, MA,
USA). The structure was informed by the objectives of the study and the pathways indicated by the clinical
data. The model pathways (Figure 3) represent that of the trial in which patients undergoing a caesarean
section were randomised to receive either cell salvage or standard care. Square boxes represent decision
nodes, for which there is a choice to be made between strategies. Circles represent chance nodes, for
which there are a number of subsequent events that could happen and each event is assigned a probability
that it will occur. Triangles represent terminal nodes, signifying the last stage in the model.
Figure 3 shows that the model starts with the choice of transfusion strategies considered in the SALVO trial:
l cell salvage
l standard care.
Women allocated to either transfusion strategy have a possibility of receiving the treatment to which they
were allocated or not. In both pathways, if the cell salvage machine was switched on, women have a
possibility of receiving cell salvage, either on its own or in combination with donor blood transfusion.
There is also a possibility that the woman may not require a transfusion.
The pathways of the model represent, as far as possible, the clinical procedures carried out in the study.
The model combines the probability of a woman following a particular path and the associated costs.
Probabilities, detailed in Table 20, were obtained from the trial and attached to each pathway. The cost and
outcome measures that were incorporated into the model were collected prospectively during the SALVO
trial using forms filled out at the pre-, intra- and postoperative phase and at the time of discharge from
hospital. Intraoperative resource use and costs were estimated as the mean cost per caesarean section
procedure conducted for each treatment pathway in the model and postoperative resource use and costs
were estimated as the mean cost per patient in both treatment strategies represented in the model.
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Data
Resource use and costs
The resource use for both groups of the trial was estimated by evaluating the individual components of
these procedures (bottom-up costing). Unit cost data were then attached to the resource use. Data were
collected on all major NHS resource use for each patient using the trial CRFs. The main resource use
monitored included the following.
Intraoperative
l Equipment and disposables required for the cell salvage procedure.
l Additional staff called into theatre solely for the purposes of cell salvage.
l Drugs used in the caesarean section procedure.
l The use of donor blood transfusion to deal with haemorrhage and its consequences.
l The use of salvaged blood transfusion to deal with haemorrhage and its consequences.
Caesarean
section
Cell salvage intended
Allocated treatment
received (cell salvage
machine is set up)
Allocated treatment
not received (cell salvage
machine is set up)
Allocated treatment
received (cell salvage
machine is set up)
Allocated treatment
not received (cell salvage
machine is set up)
p_allocated treatment rec…
p_allocated treatment rec…
Standard care intended
#
#
#
#
#
#
#
#
#
#
Salvaged blood not
returned
Donor blood transfusion
given
Donor blood transfusion
given
p_donor blood transfusion
p_donor blood transfusion
Donor blood transfusion
not given
Donor blood transfusion
not given
Salvaged blood returned
p_salvaged blood returned
Salvaged blood not
returned
Salvaged blood returned
p_salvaged blood returned
Donor blood transfusion
given
p_donor blood transfusion
Donor blood transfusion
not given
Donor blood transfusion
given
p_donor blood transfusion
Donor blood transfusion
not given
Donor blood transfusion
given
p_donor blood transfusion
Donor blood transfusion
not given
Donor blood transfusion
given
p_donor blood transfusion
Donor blood transfusion
not given
FIGURE 3 Decision tree structure.
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Postoperative
l Length and type of hospital inpatient stay including additional treatment required attributed to the
caesarean section procedure.
l The use of donor blood transfusion to deal with haemorrhage and its consequences.
Intraoperative resource use and costs
For the analysis, intraoperative resource use data were obtained from the SALVO trial. Costs were estimated
for each item to arrive at a mean cost per caesarean section procedure conducted for each treatment
pathway in the model. To estimate the cost of a caesarean section procedure some costs were calculated at
the patient level (e.g. swab washing) and some at the procedural level (e.g. drugs used in the caesarean
section procedure). This is outlined in Table 21 and further detail is provided in the subsequent sections.
Equipment and disposables required for the cell salvage procedure
Many centres reported that their cell salvage machines were obtained on lease and, as such, only the
running costs and cost of consumables would be incurred. Therefore, the acquisition costs for a cell
salvage machine were not included in the analysis but the addition of this cost was explored in a sensitivity
analysis. The costs of materials used by participating centres varied. The acquisition cost and annual
maintenance cost for a Haemonetics® Cell Saver® 5 (Haemonetics UK Ltd, Coventry, UK) machine was
TABLE 20 Probabilities used in the model
Treatment pathway
Trial data
(n/N) Probability Distribution
Cell salvage intended
Cell salvage intended→ allocated treatment received (machine was on) 1432/1498 0.96 Beta
Allocated treatment received → salvaged blood returned 726/1432 0.51 Beta
Allocated treatment received → salvaged blood not returned 703/1432 0.49 Beta
Salvaged blood returned → donor blood transfusion given 22/726 0.03 Beta
Salvaged blood returned → donor blood transfusion not given 704/726 0.97 Beta
Salvaged blood not returned → donor blood transfusion given 9/703 0.01 Beta
Salvaged blood not returned → donor blood transfusion not given 697/703 0.99 Beta
Cell salvage intended→ allocated treatment not received (machine was off) 66/1498 0.04 Beta
Allocated treatment not received → donor blood transfusion given 6/66 0.09 Beta
Allocated treatment not received → donor blood transfusion not given 60/66 0.91 Beta
Standard care intended
Standard care intended→ allocated treatment received (machine was off) 1434/1492 0.96 Beta
Allocated treatment received → donor blood transfusion given 47/1434 0.03 Beta
Allocated treatment received → donor blood transfusion not given 1387/1434 0.97 Beta
Standard care intended → allocated treatment not received (machine was on) 58/1492 0.04 Beta
Allocated treatment not received → salvaged blood returned 35/58 0.60 Beta
Allocated treatment not received → salvaged blood not returned 23/58 0.40 Beta
Salvaged blood returned → donor blood transfusion given 4/35 0.11 Beta
Salvaged blood returned → donor blood transfusion not given 31/35 0.89 Beta
Salvaged blood not returned → donor blood transfusion given 1/23 0.04 Beta
Salvaged blood not returned → donor blood transfusion not given 22/23 0.96 Beta
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TABLE 21 Intraoperative resource use and costs per procedure
Item
Resource use
Unit cost
Mean cost per procedure
Assumption/working Source
Cell salvage
(n= 1498)
Control
(n= 1492)
Cell salvage
(n= 1498)
Control
(n= 1492)
Running costs 1432 58 £6.14 £6.14 £6.14 Based on annual maintenance costs for
Haemonetics® Cell Saver® 5 (Haemonetics
UK Ltd, Coventry, UK) machine and
estimated annual usage
UHB, (Mr Scott Hancock, University Hospitals
Birmingham, 2016, personal communication);
NICE costing statement blood transfusion12
Collection set 1 1 £41.71 £41.71 £41.71 Based on the assumption that one
collection set is used per procedure
NHS Supply Chain Catalogue.74 Autotransfusion
reservoir 3 l
Processing
pack
1 1 £77 £77 £77 Based on the assumption that one
processing pack is used per procedure
NHS Supply Chain Catalogue.74 Intraoperative
autologous blood system cell saver 5+ bowl set
125 ml (Haemonetics UK Ltd, Coventry, UK)
LDF 782 25 n/a n/a n/a Cost not included in the analysis as
LDF included in the collection set for
Haemonetics Cell Saver 5 machine
NHS Supply Chain Catalogue.74 Autotransfusion
reservoir 3 l
Additional
sucker
598 29 £15.41 £6.43 £7.70 Mean cost based on the number of
additional suckers used in each
treatment group/total number of patients
who received cell salvage
NHS Supply Chain Catalogue.74 Aspiration and
anticoagulation line cell saver (Haemonetics
UK Ltd, Coventry, UK). £308.02 for 20
Swab washing 781 21 £0.80 £0.44 £0.29 Mean cost based on the number of times
swabs were washed in each treatment
group/total number of patients who
received cell salvage
ICS Factsheet 1 Swab Washing March 2015,75
based on the cost of 1 l of 0.9% sodium
chloride, BNF76
Staff £0.72 (minute) £11.57 £12.03 Based on the staff type most frequently
called into theatre
Unit cost for hospital based nurse, band 5,
PSSRU unit costs 2015 (costs include
qualifications)77
Saline (l) 2 2 £0.80 £1.60 £1.60 Based on the assumption that 2 l of
saline would be administered to all
patients undergoing cell salvage prior to
collection12
Based on the cost of 1 l of 0.9% sodium
chloride, BNF76
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Item
Resource use
Unit cost
Mean cost per procedure
Assumption/working Source
Cell salvage
(n= 1498)
Control
(n= 1492)
Cell salvage
(n= 1498)
Control
(n= 1492)
Heparin
sodium
(30,000 IU)
2 2 £10.60 £21.20 £21.20 Based on the assumption that 60,000 IU
of heparin sodium would be
administered to all patients undergoing
cell salvage prior to collection12
Based on the cost of a 1-ml amp of heparin
sodium 25,000 IU/ml and a 1-ml amp of heparin
sodium 5000 IU/ml, BNF76
Anti-D
(500 IU)
1 1 £33.75 £3.04 £3.04 Based on the assumption that all
RhD-negative women delivering a
RhD-positive baby receive at least 500 IU
of anti-D.34 Mean cost per procedure
based on the probability of a woman
requiring anti-D in each treatment group
(0.09)
Based on the cost of 500-unit vial of anti-D
immunoglobulin, BNF76
Anti-D
(1500 IU)
1 1 £58 £5.22 £5.22 Based on the assumption that women
who receive cell salvage are offered
1500 IU of anti-D.34 Mean cost per
procedure based on the probability of a
woman requiring anti-D in each
treatment group (0.09)
Based on the cost of 1500-unit vial of anti-D
immunoglobulin, BNF76
RBC
transfusion
(units)
3 3 First unit:
£194;
subsequent
units: £166
£520 £520 Based on the assumption that all units
transfused in each treatment group were
RBCs12
NICE costing statement for blood transfusion.12
Unit cost for RBCs obtained from NHSBT 2016/1778
amp, ampoule; BNF, British National Formulary; ICS, intraoperative cell salvage; n/a, not applicable; NHSBT, NHS Blood and Transplant.
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obtained from one centre. Costs for consumables were sourced from the NHS Supply Chain Catalogue
(August 2016)74 and correspond to the consumables used with this machine. The annual number of
procedures that would use the cell salvage machine was based on the NICE costing statement for blood
transfusion published in November 2015.12
The Haemonetics Cell Saver 5 machine uses two separate kits of consumables for collection and reinfusion.
In the SALVO trial, some centres (n = 202 participants treated; see Table 11) used a continuous transfusion
cell-saver machine that required the use of different consumables. However, for this analysis it was
assumed that each centre used one set of consumables for collection and reinfusion. This was tested in a
sensitivity analysis. The cost of a collection set and processing pack (used for reinfusion) with a 125 ml
bowl for a Haemonetics Cell Saver 5 machine was obtained from the NHS Supply Chain Catalogue (August
2016).74 For some cell salvage procedures in the study (n = 807), a LDF was used, but this filter was not
used in the remaining 683 procedures. As this item is included in the collection set, no additional cost was
incurred. Contained in the processing pack is one aspiration and anticoagulation line (sucker). For some
caesarean section procedures in the study (n = 627), an additional sucker was used and this additional cost
was apportioned across all caesarean section procedures for which cell salvage was conducted. The cost
of an additional sucker was obtained from the NHS Supply Chain Catalogue (August 2016)74 and the total
cost based on usage was divided by the number of patients in each group of the trial that set up the
cell-saver machine to arrive at a mean cost of the procedure per patient in each group.
Blood loss can also be removed from the operative site by swabs. By washing swabs, the blood that is
normally discarded can be collected and the overall efficiency of red cell recovery improved.61 Swab
washing occurred in 802 procedures in the SALVO trial, 781 procedures in the cell salvage group and 21
procedures in the control group. The UK Cell Salvage Action Group recommends that swabs are washed in
1 l of saline.75 The cost of saline (0.9% sodium chloride) was obtained from the British National Formulary
(BNF).76 The total cost of swab washing in each group of the trial was apportioned by the number of
patients who received cell salvage in that group of the trial.
Additional staff called into theatre solely for the purposes of cell salvage
The amount of time additional staff, called into theatre solely for the purposes of cell salvage, spent in
the operating theatre was recorded in the SALVO trial. Staff grade was identified at a broad level [nurse,
operating department practitioner (ODP) and doctor] and job band distinction was not recorded, but it was
frequently included in the notes if a midwife was called into theatre. The analysis is based on the staff type
most frequently called into theatre (ODP in both groups) and assumed the lowest possible cost within this
job grade (hospital-based nurse, band 5). Staff unit costs were obtained from the Personal Social Services
Research Unit (PSSRU) unit costs (2015).77 The total cost of additional staff required for cell salvage was
distributed by the number of times the cell salvage machine was set up in both groups of the trial.
Drugs used in the caesarean section procedure
Typically saline and an anticoagulant (e.g. heparin sodium) would be used for people undergoing cell
salvage. The saline is required for collection of the blood (separate to saline used for swab washing) and
the heparin sodium to stop the collected blood clotting.12 It was assumed, as per the NICE costing
statement, that 2 l of saline and 60,000 IU heparin sodium (30,000 IU per litre of saline) would be used for
collection in any caesarean section procedure for which the cell salvage machine was turned on.12 The cost
of saline (0.9% sodium chloride) and heparin sodium were obtained from the BNF.76 These costs were
added to the average cost of the cell salvage procedure.
Guidelines suggest that all RhD-negative unsensitised women delivering a RhD-positive baby should be
routinely offered a standard dose of anti-D immunoglobulin (at least 500 IU) as prophylaxis to minimise this
risk of sensitisation, and all women who receive cell salvage should be offered a higher dose (1500 IU).34
The probability of a woman requiring administration of anti-D (i.e. a RhD-negative mother with RhD-positive
baby) was 0.09 in both groups of the SALVO trial. The cost of anti-D immunoglobulin was obtained from
the BNF76 and the total cost based on usage was divided by the number of women in each arm of the
model to arrive at a mean cost per patient in each treatment pathway.
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Donor blood transfusion
The cost of donor blood transfusion used in the model was based on the costing methodology employed
by NICE in which the resource use and costs for both blood bank and ward procedures were split to reflect
the cost of transfusing the first unit and the cost of transfusing subsequent units.12 For simplicity, the cost
of transfusion of RBCs is used in the model. RBCs made up the largest proportion of the blood products
transfused in the SALVO trial. Adjusting the cost of transfusion to reflect the different proportions of
different blood products transfused is complex and unlikely to result in a significant cost difference. This
approach is supported by NICE.12 The unit cost of RBCs was taken from NHS Blood and Transfusion list
price for 2016/17.78 The mean number of units transfused per patient in each group of the trial was
obtained and rounded up to represent the fact that any remaining blood in a unit would be disposed.
The following approach was taken to calculate the mean cost:
CostTransfusion = CostFirstUnit + CostSubsequentUnits. (1)
All patients in the model required blood grouping and antibody screening, even if they did not end up
requiring a donor blood transfusion. The cost of these procedures was obtained from the NICE costing
statement12 and applied one time to people in the model who did not receive a donor blood transfusion.
Note that for those who did receive a donor blood transfusion, this cost is incorporated into the cost of the
first unit of blood.
Postoperative resource use and costs
For the analysis, postoperative resource use data were obtained from the SALVO trial. Costs were estimated
for each item based on their occurrence in each branch of the model to arrive at a mean cost per patient
for each branch. This is outlined in Table 22 and further detail is provided in the subsequent sections.
Length and type of hospital inpatient stay
Total time in hospital was recorded for each participant in the SALVO trial (cell salvage group mean = 2.64 days,
standard care group mean= 2.72 days). Within the trial a HLC form was completed for 212 patients. This form
indicated the number of days or partial days the patient received level 0, 1, 2 and 3 care. For this study, a partial
day was costed as half a full day. Level 0 care is defined in the trial literature as ‘patients whose needs can be
met through general ward care’. Admission to HLC for which level 0 care was administered was therefore
costed as normal care. The total number of days spent receiving HLC (level 1–3) was deducted from the total
time spent in hospital to arrive at the total number of days in normal care for each group. The weighted
average cost per inpatient day was obtained from NHS Reference Costs 2014/201579 (Table 23) and was
applied to arrive at a mean cost per patient of normal care.
The cost for a day receiving level 3 care was obtained from the 2016/17 National Prices80 maternity pathway,
which gives costs for a day of intensive care. Information on the cost per day at level 1 and 2 was not available.
For the purposes of this study it was assumed that level 1 care was 25% more expensive per day than level 0
care and level 2 care was 25% more expensive than level 1 care (Table 24). The following approach was taken
to calculate the mean cost per patient in each arm of the model (Table 25):
CostHLC = (TotalCostLevel1Care + TotalCostLevel2Care + TotalCostLevel3Care)/npatients. (2)
Adverse events
Although the occurrence of all AEs deemed relevant to the procedure were recorded as a categorical
outcome (yes/no), only clinically defined SAEs that occurred within the trial and were deemed relevant to the
procedure were considered potentially relevant to this analysis (n = 2). This is based on the assumption that
non-SAEs deemed relevant to the procedure would have limited or zero resource impact. The two AEs
considered potentially relevant to this analysis were recorded in the trial as life-threatening acute transfusion
reactions. Guidelines recommend that for life-threatening acute transfusion reactions, the correct procedure
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TABLE 22 Postoperative resource use and costs
Item
Resource use
Unit cost
Mean cost per patient
Assumption/working Source
Cell salvage
(n= 1498)
Control
(n= 1492)
Cell salvage
(n= 1498)
Control
(n= 1492)
Inpatient stay
(normal days)
3734.5 3852 £431.45 £1074 £1113 See Tables 23 and 25 NHS Reference Costs 2014/201579
Inpatient stay
(HLC days)
189.5 136 See Table 24 £78 £56 See Tables 24 and 25 NHS Reference Costs 2014/2015.79
2016/17 National Prices80
AEs 3 0 n/a n/a n/a Based on the assumption that
transfusion would be discontinued in
the event of an adverse reaction
BCSH guidelines81
Hospital transfer 2 2 £99 £0.13 £0.13 n/a PSSRU 201577
Investigations 6 10 See Table 27 £0.42 £0.70 n/a NHS Reference Costs 2014/201579
Additional
surgery
11 8 See Table 28 £13 £9 See Table 34 NHS Reference Costs 2014/201579
RBC transfusion
(units)
3 3 First unit: £190.
Subsequent
units: £165
£13 £17 Based on the assumption that all units
transfused in each treatment group
were RBCs
NICE costing statement for blood
transfusion.12 Unit cost for RBCs obtained
from NHSBT 2016/1778
Total cost of postnatal care per patient £1178.55 £1195.83
BCSH, British Committee for Standards in Haematology; n/a, not applicable; NHSBT, NHS Blood and Transplant.
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is to discontinue transfusion.81 Therefore, no additional costs were incurred and the occurrence of AEs is not
included in this analysis.
Hospital transfer
Costs for hospital transfer were obtained from PSSRU.77 The following approach was taken to calculate the
mean cost per patient in each arm of the model (Table 26):
CostHospitalTransfer = TotalCostHospitalTransfer × ProbabilityHospitalTransfer. (3)
Investigations
Data on the number of X-rays, computed tomography (CT) scans and magnetic resonance imaging (MRI)
scans were recorded in the SALVO trial. As stated in NHS Reference Costs 2014/2015,79 plain film X-rays
TABLE 23 Cost per inpatient day of normal care
Currency code Currency description Activity National average unit cost (£)
Elective inpatient excess bed-days
NZ50A Planned caesarean section with a CC score of 4+ 11 99.22
NZ50B Planned Caesarean Section with a CC score of 2 or 3 46 415.20
NZ50C Planned caesarean section with a CC score of 0 or 1 116 740.07
NZ51A Emergency caesarean section with a CC score of 4+ 12 358.93
NZ51B Emergency caesarean section with a CC score of 2 or 3 83 231.87
NZ51C Emergency caesarean section with a CC score of 0 or 1 93 311.29
Non-elective inpatient excess bed-days
NZ50A Planned caesarean section with a CC score of 4+ 2316 412.57
NZ50B Planned caesarean section with a CC score of 2 or 3 7670 438.31
NZ50C Planned caesarean section with a CC score of 0 or 1 6022 437.22
NZ51A Emergency caesarean section with a CC score of 4+ 2840 408.49
NZ51B Emergency caesarean section with a CC score of 2 or 3 5388 417.82
NZ51C Emergency caesarean section with a CC score of 0 or 1 9806 440.84
Weighted average cost per inpatient day 431.00
CC, complication and comorbidity.
TABLE 24 Level of care
Level of care Cost per day (£) Assumption/working Source
0 431 See Table 23 NHS Reference Costs 2014/201579
1 539 Based on the assumption that level 1 care is
25% more expensive than level 0 care
n/a
2 674 Based on the assumption that level 2 care is
25% more expensive than level 1 care
n/a
3 848 n/a 2016/17 National Prices80
n/a, not applicable.
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TABLE 25 Inpatient stay resource use and costs
Item Source/working
Cell salvage
(n= 1498)
Control
(n= 1492)
Normal days in hospital
Total days in hospital Trial data 3924 3988
Total days in HLC Trial data (level 1–3) 189.5 136
Total normal days Total days in hospital minus total days in
HLC
3734.5 3852
Cost per normal day (£) See Table 23 431 431
Total cost for normal days in hospital (£) Total normal days × cost per day 1,609,354 1,660,212
Cost per patient (£) Total cost/number in trial group 1074 1113
HLC days in hospital
Total days spent at level 1 care Trial data 96.5 67.5
Cost per day at level 1 care (£) See Table 24 539 539
Total cost per treatment arm (£) Total normal days × cost per day 52,014 36,383
Total days spent at level 2 care Trial data 84.5 67
Cost per day at level 2 care (£) 2016/17 National Prices80 674 674
Total cost per treatment arm (£) Total days × cost per day 56,953 45,158
Total days spent at level 3 care Trial data 8.5 1.5
Cost per day at level 3 care (£) 2016/17 National Prices80 848 848
Total cost per treatment arm (£) Total days × cost per day 7208 1272
Total cost of HLC per treatment arm (£) Total cost level 1 + 2+ 3 116,175 82,813
Cost per patient (£) Total cost/number in trial group 78 56
TABLE 26 Hospital transfer resource use and costs
Item Source/working
Cell salvage
(n= 1498)
Control
(n= 1492)
Resource use Trial data 2 2
Unit cost (£) Based on cost per ambulance service.
PSSRU 201577
99 99
Total cost (£) Resource use × unit cost 198 198
Number of patients requiring hospital
transfer
Trial data 2 2
Probability of hospital transfer Number of patients requiring hospital
transfer/number in trial group
0.0013 0.0013
Cost per patient (£) Total cost per patient × probability 0.13 0.13
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that are part of an admission or outpatient attendance are not reported separately owing to their high
volume and low cost. Therefore, occurrence of X-rays is not included in this analysis. Costs for CT scans
and MRI scans were obtained from NHS Reference Costs 2014/2015.79 The following approach was taken
to calculate the mean cost per patient in each arm of the model (Table 27):
CostInvestigations = TotalCostInvestigations × ProbabilityInvestigations. (4)
Additional surgery
A total of 24 additional surgeries were recorded in the SALVO trial (cell salvage group n = 15, control group
n = 9). The cost for each additional surgery was obtained from NHS Reference Costs 2014/2015.79 The cost
for time spent in hospital as a result of the additional surgery was subtracted from the NHS reference cost
on the assumption that these costs would have been incorporated in the cost of hospital inpatient stay. The
following approach was taken to calculate the mean cost per patient in each arm of the model (Table 28):
CostAdditionalSurgery = TotalCostAdditionalSurgery × ProbabilityAdditionalSurgery. (5)
Donor blood transfusion
The cost of donor blood transfusion received postnatally is based on the same costs as those used for
transfusion received intraoperatively in this model. For simplicity, the cost of transfusion of RBCs is used.
The mean number of units transfused to each patient in each group of the trial was obtained and rounded
up to represent the fact that any remaining blood in a unit would be disposed of. The following approach
was taken to calculate the mean cost per patient in each arm of the model (Table 34):
CostTransfusion = (CostFirstUnit + CostSubsequentUnits) × ProbabilityTransfusion PostOp. (6)
TABLE 27 Investigations resource use and costs
Item Source/working
Cell salvage
(n= 1498)
Control
(n= 1492)
CT scan
Resource use Trial data 6 9
Unit cost (£) NHS Reference Costs 2014/201579 94 94
Total cost (£) Resource use × unit cost 564 846
MRI scan
Resource use Trial data 0 1
Unit cost (£) NHS Reference Costs 2014/201579 n/a 138
Total cost (£) Resource use × unit cost n/a 138
Total cost investigations (£) Total cost CT+ total cost MRI 564 984
Number of patients requiring investigations Trial data 4 7
Probability of requiring investigations Number of patients requiring investigations/
number in trial group
0.003 0.005
Cost per patient (£) Total cost per patient × probability 0.42 0.70
n/a, not applicable.
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TABLE 28 Additional surgeries resource use and costs
Item
Resource use
Unit
cost (£)
Total cost (£)
Source
Cell salvage
(n= 1498)
Control
(n= 1492)
Cell salvage
(n= 1498)
Control
(n= 1492)
Sutures 2 2 2991 5982 5982 NHS Reference Costs
2014/201579
Hysterectomy 3 2 1621 4863 3242 NHS Reference Costs
2014/201579 (Table 29)
Laparotomy 3 2 690 2070 1380 NHS Reference Costs
2014/201579 (Table 30)
Evacuation 2 2 1042 2084 2084 NHS Reference Costs
2014/201579 (Table 31)
Colon procedure 2 0 1088 2176 n/a NHS Reference Costs
2014/201579 (Table 32)
Bowel procedure 0 1 399 n/a 399 NHS Reference Costs
2014/201579 (Table 33)
Drainage 3 0 690 2070 n/a NHS Reference Costs
2014/201579
Total cost additional surgery 19,245 13,087
Number of patients
requiring additional surgery
11 8
Probability of requiring
additional surgery
0.0073 0.0054
Cost per patient (£) 13 9
n/a, not applicable.
TABLE 29 Hysterectomy procedure cost
Currency
code Currency description Activity
National
average
Average length of stay
(days)
Unit cost (£) Elective Non-elective
MAO7E Major open upper genital tract procedures with a
CC score of 5+
578 5909.25 5.37 11
MAO7F Major open upper genital tract procedures with a
CC score of 3–4
1780 4387.14 3.49 6
MAO7G Major open upper genital tract procedures with a
CC score of 0–2
24,190 3511.27 2.49 3
MAO8A Major, laparoscopic or endoscopic, upper genital
tract procedures with a CC score of 2+
3076 3445.44 1.86 3
MAO8B Major, laparoscopic or endoscopic, upper genital
tract procedures with a CC score of 0 or 1
16,845 2889.92 1.47 2
Weighted average cost per procedure (£) 3345
Average length of stay (days) 4
Cost per day of care (level 0) (£) 431
Total cost of hospital stay (£) 1724
Average cost per procedure excluding cost of hospital stay (£) 1621
CC, complication and comorbidity.
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TABLE 30 Laparotomy procedure cost
Currency
code Currency description Activity
National
average
Average length of stay
(days)
Unit cost (£) Elective Non-elective
MA10Z Minor, laparoscopic or endoscopic, upper genital
tract procedures
17,787 1341.48 1.02 2
Average cost per procedure (£) 1341
Average length of stay (days) 1.51
Cost per day of care (level 0) (£) 431
Total cost of hospital stay (£) 651
Average cost per procedure excluding cost of hospital stay (£) 690
TABLE 31 Evacuation procedure cost
Currency
code Currency description Activity
National
average
Average length of stay
(days)
Unit cost (£) Elective Non-elective
MA17D Dilatation and evacuation, 14–20 weeks’
gestation
763 2011.19 1.60 3
Average cost per procedure (£) 2011
Average length of stay (days) 2.25
Cost per day of care (level 0) (£) 431
Total cost of hospital stay (£) 969
Average cost per procedure excluding cost of hospital stay (£) 1042
TABLE 32 Colon procedure cost
Currency
code Currency description Activity
National
average
Average length of stay
(days)
Unit cost (£) Elective Non-elective
FZ75C Proximal colon procedures, ≥ 19 years, with a CC
score of 6+
809 8952.50 11.26 16
FZ75D Proximal colon procedures, ≥ 19 years, with a CC
score of 3–5
2139 6751.80 7.18 11
FZ75E Proximal colon procedures, ≥ 19 years, with a CC
score of 0–2
6430 5795.71 5.28 8
Weighted average cost per procedure (£) 6286
Average length of stay (days) 10
Cost per day of care (level 0) (£) 431
Total cost of hospital stay (£) 5198
Average cost per procedure excluding cost of hospital stay (£) 1088
CC, complication and comorbidity.
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Outcomes
The outcome of interest in the trial was the use of donor blood transfusion in response to haemorrhage
and its consequences.
Assumptions
It was necessary to make the following pragmatic assumptions before the analysis could be carried out:
1. Trial centres.
All of the centres involved in the trial were assumed to have the same expertise and to have followed
similar protocols in the management of patients.
TABLE 33 Small bowel procedure cost
Currency
code Currency description Activity
National
average
Average length of stay
(days)
Unit cost (£) Elective Non-elective
FZ67C Major small intestine procedures, ≥ 19 years, with a
CC score of 7+
860 9719.99 15.84 21
FZ67D Major small intestine procedures, ≥ 19 years, with a
CC score of 4–6
1476 7127.58 8.86 14
FZ67E Major small intestine procedures, ≥ 19 years, with a
CC score of 2 or 3
2751 5164.47 5.83 10
FZ67F Major small intestine procedures, ≥ 19 years, with a
CC score of 0 or 1
4662 3561.35 4.66 7
Weighted average cost per procedure (£) 5097
Average length of stay (days) 11
Cost per day of care (level 0) (£) 431
Total cost of hospital stay (£) 4703
Average cost per procedure excluding cost of hospital stay (£) 399
CC, complication and comorbidity.
TABLE 34 Blood transfusion resource use and costs
Item Source/working
Cell salvage
(n= 1498)
Control
(n= 1492)
Resource use (mean units transfused) Trial data 3 3
Unit cost: first unit NHSBT 201678, NICE costing statement
for blood transfusion12
£190 £190
Unit cost: subsequent units NHSBT 201678, NICE costing statement
for blood transfusion12
£165 £165
Total cost Resource use × unit cost £520 £520
Number of patients requiring transfusion Trial data 38 49
Probability of transfusion Number of patients requiring
transfusion/number in trial group
0.025 0.033
Cost per patient Total cost per patient × probability £13 £17
NHSBT, NHS Blood and Transplant.
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2. Equipment and disposables required for the cell salvage procedure.
It was assumed that all centres performing cell salvage used consumables and that one collection set
and one processing pack were used per cell salvage procedure. Costs for equipment and disposables
were obtained for a Haemonetics Cell Saver 5 machine. Variance in costs was explored in sensitivity
analysis. When swab washing occurred, it was assumed that the swabs were washed in 1 l of saline.75
3. Use of cell salvage machine.
When the cell salvage machine was switched on, it was assumed that running costs would be incurred
and a collection set would be used even if no salvaged blood was returned to the patient. It was also
assumed that heparin sodium and saline would be used prior to collection.12
4. Additional staff called into theatre solely for the purposes of cell salvage.
We based our analysis on the staff type most frequently called into theatre in the trial and assumed
the lowest possible cost within this job band distinction. Staff cost variance was explored through
sensitivity analysis.
5. Salvaged blood.
The threshold setting on a cell salvage machine to process can be set to engage for salvaged blood
above a certain volume and in this study trial centres displayed variance in the minimum volume
threshold they selected. Trial guidance given to participating centres stated that all processed blood
produced by the machines should be returned to the patient. This analysis assumed that all minimum
threshold settings were disengaged. The cost of collection of all shed blood was considered, regardless
of whether or not that blood was subsequently returned to the patient.
6. Donor blood.
All units transfused were assumed to be RBCs.12 The mean number of units transfused per patient
was rounded up to account for the fact that any remaining blood in a bag would be disposed of.
7. Length and type of inpatient stay.
For those patients who received level 0 care when admitted to HLC, it was assumed that their needs
could be met through general ward care. It was assumed that level 1 care was 25% more expensive
per day than level 0 care and level 2 care was 25% more expensive than level 1 care.
8. Additional surgeries.
Additional surgeries were included in this analysis with the cost of inpatient bed-days excluded to
avoid double counting. Inpatient bed-days were assumed to be the equivalent of level 0 care.
9. AEs.
It was assumed that non-SAEs deemed relevant to the procedure would have limited or zero resource
impact. It was assumed that in the case of an acute transfusion reaction, the transfusion would
be discontinued.11
10. Infant health.
In this study, the health of the infant was not considered relevant to the intervention. Information
relating to the clinical status and care of the infant was therefore not included in the analysis.
Analysis
Given the objectives of the trial and the duration of follow-up, a within-trial economic analysis was carried
out. The analysis took the perspective of the NHS following current recommendations from NICE.82
The main economic analysis was a cost-effectiveness analysis with results expressed as cost per donor
transfusion avoided.
We carried out three main analyses on the trial data. In analysis 1, the base case was based on the ITT
principle. In this method, patients are compared within the treatment groups to which they were originally
randomised irrespective of the treatment received.83 This method of analysis allows the estimates to follow
real-life scenarios in which patients may not always receive the planned treatment. Not using ITT analysis
can often exaggerate the benefits of a given intervention.83
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Analysis 2 was based on the treatment received by patients irrespective of randomisation (the PP analysis).
Within the SALVO trial, equal numbers of patients were randomised to either the cell salvage or control
group. However, because some clinicians managing women in the control group had access to a cell
salvage machine, it was possible that women in the control group could receive cell salvage in place of a
donor blood transfusion. A PP analysis was carried out to look at the effect of treatment received on the
outcome estimates. Therefore, in analysis 2, all patients who received cell salvage were compared with
those who received standard care, irrespective of the treatment to which they were randomised.
Analysis 3 considered only patients who underwent an emergency caesarean section. This analysis was
considered necessary as the SALVO trial found that numerically, there was a greater reduction in rate of
transfusion within the emergency patient group than the elective patient group. This analysis followed the
same methodology as analyses 1 and 2. Probabilities were obtained from the trial and attached to each
pathway in the existing model. For the analysis, intra- and postoperative resource use data were obtained
from the SALVO trial. Intraoperative costs were estimated for each item to arrive at a mean cost per
caesarean section procedure for each treatment pathway in the model. Postoperative costs were estimated
for each item based on their occurrence in each branch of the model to arrive at a mean cost per patient
for each branch (Tables 35–37).
TABLE 35 Probabilities used in the emergency caesarean section model
Treatment pathway
Trial data
(n/N) Probability Distribution
Cell salvage intended
Cell salvage intended → allocated treatment received (machine was on) 794/833 0.953 Beta
Allocated treatment received → salvaged blood returned 390/794 0.491 Beta
Allocated treatment received → salvaged blood not returned 401/794 0.509 Beta
Salvaged blood returned → donor blood transfusion given 5/390 0.013 Beta
Salvaged blood returned → donor blood transfusion not given 385/390 0.987 Beta
Salvaged blood not returned → donor blood transfusion given 2/401 0.005 Beta
Salvaged blood not returned → donor blood transfusion not given 399/401 0.995 Beta
Cell salvage intended → allocated treatment not received (machine was off) 39/833 0.047 Beta
Allocated treatment not received → donor blood transfusion given 1/39 0.026 Beta
Allocated treatment not received → donor blood transfusion not given 38/39 0.974 Beta
Standard care intended
Standard care intended → allocated treatment received (machine was off) 780/808 0.965 Beta
Allocated treatment received → donor blood transfusion given 9/780 0.012 Beta
Allocated treatment received → donor blood transfusion not given 771/780 0.988 Beta
Standard care intended→ allocated treatment not received (machine was on) 28/808 0.035 Beta
Allocated treatment not received → salvaged blood returned 14/28 0.5 Beta
Allocated treatment not received → salvaged blood not returned 14/28 0.5 Beta
Salvaged blood returned → donor blood transfusion given 1/14 0.071 Beta
Salvaged blood returned → donor blood transfusion not given 13/14 0.929 Beta
Salvaged blood not returned → donor blood transfusion given 0/14 0 Beta
Salvaged blood not returned → donor blood transfusion not given 14/14 1 Beta
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TABLE 36 Emergency caesarean section intraoperative resource use and costs per procedure
Item (units)
Resource use
Unit cost (£)
Mean cost per procedure (£)
Assumption/working Source
Cell salvage
(n= 833)
Control
(n= 808)
Cell salvage
(n= 833)
Control
(n= 808)
Running costs 6.14 6.14 6.14 Based on annual maintenance costs for
Haemonetics Cell Saver 5 machine and
estimated annual usage
UHB, (Mr Scott Hancock, University
Hospitals Birmingham, 2016, personal
communication). NICE costing
statement blood transfusion12
Collection set 1 1 41.71 41.71 41.71 Based on the assumption that one
collection set is used per procedure
NHS Supply Chain Catalogue 2015:74
autotransfusion reservoir 3 litre
Processing pack 1 1 77.00 77.00 77.00 Based on the assumption that one
processing pack is used per procedure
NHS Supply Chain Catalogue 2015:74
intraoperative autologous blood
system cell saver 5+ bowl set 125 ml
Filter n/a n/a n/a n/a n/a No usage of LDF recorded in the trial n/a
Additional sucker 321 14 15.41 6.23 7.70 Mean cost based on the number of
additional suckers used in each
treatment arm/total number of patients
who received cell salvage
NHS Supply Chain Catalogue 2015:74
aspiration and anticoagulation line
cell saver. £308.02 for 20
Swab washing 444 11 0.80 0.45 0.31 Mean cost based on the number of times
swabs were washed in each treatment
arm/total number of patients who
received cell salvage
ICS Factsheet 1 Swab Washing
March 2015,75 based on the cost of
1 l 0.9% of sodium chloride, BNF76
Staff 82.21
(minutes)
30
(minutes)
0.72 (minutes) 11.70 1.54 Based on the staff type most frequently
called into theatre
Unit cost for hospital based nurse,
band 5, PSSRU unit costs 2015
(costs include qualifications)77
Saline (l) 2 2 0.80 1.60 1.60 Based on the assumption that 2 l of
saline would be administered to all
patients undergoing cell salvage prior to
collection
Based on the cost of 1 l of 0.9%
sodium chloride, BNF76
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TABLE 36 Emergency caesarean section intraoperative resource use and costs per procedure (continued )
Item (units)
Resource use
Unit cost (£)
Mean cost per procedure (£)
Assumption/working Source
Cell salvage
(n= 833)
Control
(n= 808)
Cell salvage
(n= 833)
Control
(n= 808)
Heparin sodium
(30,000 IU)
2 2 10.60 21.20 21.20 Based on the assumption that 60,000 IU
heparin sodium would be administered
to all patients undergoing cell salvage
prior to collection
Based on the cost of a 1-ml amp of
heparin sodium 25,000 IU/ml and
a 1-ml amp of heparin sodium
5000 IU/ml, BNF76
Anti-D (500 IU) 1 1 33.75 3.04 3.04 Based on the assumption that all
RhD-negative women delivering a
RhD-positive baby receive at least 500 IU
of anti-D. Mean cost per procedure
based on the probability of a woman
requiring anti-D in each treatment arm
(0.09)
Based on the cost of 500-unit vial of
anti-D immunoglobulin, BNF76
Anti-D (1500 IU) 1 1 58.00 5.22 5.22 Based on the assumption that women
who receive cell salvage are offered
1500 IU of anti-D. Mean cost per
procedure based on the probability of
a woman requiring anti-D in each
treatment arm (0.09)
Based on the cost of 1500-unit vial
of anti-D immunoglobulin, BNF76
RBC transfusion 2 3 First unit: 190
Subsequent
units: 165
355 520 Based on the assumption that all units
transfused in each treatment arm were
RBCs
NICE costing statement for blood
transfusion.12 Unit cost for RBCs
obtained from NHSBT 2016/1778
amp, ampoule; n/a, not applicable; NHSBT, NHS Blood and Transplant.
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Sensitivity analysis
Deterministic sensitivity analyses and probabilistic sensitivity analyses (PSAs) were carried out for each
analysis to explore the effects of the inherent uncertainty in parameter estimates on model results.
Deterministic sensitivity analysis involves varying one or more parameters while keeping the others at their
baseline value. Although deterministic sensitivity analyses can be helpful to identify which model inputs
are important in driving a decision or to identify threshold values, comprehensive representation can be
obtained by undertaking a probabilistic sensitivity analysis (PSA), in which the uncertainty around a parameter
is represented with a probability distribution. Monte Carlo simulation was used to sample from these
distributions to allow the effect of parameter uncertainty to be evaluated. This involved 1000 repeated
random draws from the distributions to indicate how variation in the model parameters would affect the
results and hence illustrate the decision uncertainty. Beta distributions were used for probability data and
Gamma distributions for costs.84,85
The results of the analyses are presented in terms of incremental cost-effectiveness ratios (ICERs), which
reflect the additional cost per donor blood transfusion avoided of cell salvage compared with standard
care. The results of the cost-effectiveness analysis are presented using scatterplots and cost-effectiveness
acceptability curves (CEACs) to reflect sampling variation and uncertainties in the appropriate threshold
cost-effectiveness value.
TABLE 37 Emergency caesarean postoperative resource use and costs per patient
Item
Resource use
Unit cost (£)
Mean cost per
patient (£)
Assumption/
working Source
Cell
salvage
(n= 833)
Control
(n= 808)
Cell
salvage
(n= 833)
Control
(n= 808)
Inpatient stay
(normal days)
2212 2246 431 1147 1205 See Tables 23
and 25
NHS Reference Costs
2014/201579
Inpatient stay
(HLC)
135 99.5 See Table 24 100 78 See Tables 24
and 25
NHS Reference Costs
2014/2015.79
National tariff
payment system
2016/1780
AEs n/a n/a n/a n/a n/a No AEs
recorded in
the trial
Hospital transfer 1 2 99 0.12 0.25 n/a PSSRU 201577
Investigations 2 6 See Table 27 0.23 0.75 n/a NHS Reference Costs
2014/201579
Additional surgery 8 3 See Table 28 11 3 See Table 34 NHS Reference Costs
2014/201579
RBC transfusion
(units)
3 3 First unit: 190.
Subsequent
units: 165
13 19 Based on the
assumption
that all units
transfused
in each
treatment arm
were RBCs
NICE costing
statement for
blood transfusion
(November 2015).12
Unit cost for RBCs
obtained from
NHSBT 2016/1778
Total cost of postnatal care per patient 1271 1306
n/a, not applicable; NHSBT, NHS Blood and Transplant.
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Deterministic sensitivity analyses
A number of deterministic sensitivity analyses were conducted in each analysis:
1. Equipment and disposables required for the cell salvage procedure.
The main analyses used costs for consumables based on a particular model of cell-saver machine.
To assess the difference that variation in these estimates would make, the unit costs were replaced
with unit costs obtained from the NICE costing statement for blood transfusion.12 We then explored
the impact of the inclusion of acquisition costs for a cell salvage machine and the impact of using a
continuous transfusion cell salvage machine that requires a suction set and reservoir (prices sourced
from participating unit) when the machine is only set up for processing in patients having blood
returned and when swab washing was not conducted.
2. Staff.
The main analyses used the mean length of time additional staff were present in theatre in each group
solely for the purposes of cell salvage. We explored the impact of not calling an additional member of
staff into theatre.
3. Donor blood.
To facilitate robust evaluation in cost-effectiveness analyses relating to donor blood, a comprehensive
estimate for the cost of a unit of donor blood is required. The NHS Blood and Transplant Authority
has valued the cost of RBCs to be £120 per unit based on direct costs to the health-care services;78
however, there is significant uncertainty surrounding this figure. We conducted a study (submitted for
publication; McLoughlin C, Roberts T, Jackson L, University of Birmingham, 2017) parallel to the SALVO
trial that aimed to dissect the current price of blood. We explored what elements are contributing to
the current cost of blood and what elements are missing. Our study concluded that the current costing
approach of assuming there will always be an adequate supply of donor blood must be replaced with
including provisions for the continued shrinking of the donor pool and the impact that future shocks to
the blood supply system could have. The sensitivity analysis assessed the difference that variation in the
estimated cost of blood made to the overall cost-effectiveness of cell salvage.
Results
Analysis 1: intention to treat
The results of the analysis are shown in Table 38. The strategy in which standard care was intended was
the least costly, with the average cost per patient estimated at £1244. However, the cell salvage intended
group was only slightly more expensive, with the average cost per patient estimated at £1327. The
cell-salvage-intended strategy was the most effective at avoiding a transfusion. The estimated incremental
cost-effectiveness ratio (ICER) for the cell-salvage-intended strategy compared with standard care was
£8110 per donor blood transfusion avoided. This means that it would cost an additional £8110 to avoid a
donor blood transfusion through cell salvage compared with standard care.
The scatterplot (Figure 4) shows the modelled uncertainty in the cost and effectiveness of the cell salvage
intended strategy compared with the standard care intended strategy from 1000 Monte Carlo simulations.
In this, the ICER of each simulation is plotted on the cost-effectiveness plane providing information about
TABLE 38 Results for the base-case analysis
Transfusion strategy Average cost per patient (£) Effectiveness: donor blood transfusion avoided ICER (£)
Standard care intended 1244 0.965
Cell salvage intended 1327 0.975 8110
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the joint density of the differences in cost and effectiveness between the two strategies. From Figure 4,
it is evident that although cell salvage is a more effective transfusion strategy, it is uncertain whether it is
more or less costly than standard care. The CEAC (Figure 5) shows that the probability that cell salvage is
cost-effective increases as the willingness to pay for a donor blood transfusion avoided increases. Given
that there is not a prespecified threshold of willingness to pay for a blood transfusion avoided, as in the
case of QALYs of £20,000–30,000 are the recommended cut-off points by NICE, the identification of
the probability of cell salvage being cost-effective is less straightforward. However, the CEAC shows that
if the maximum willingness to pay for a donor blood transfusion avoided was, for example, £50,000, the
probability of cell salvage being cost-effective would be 62%.
Analysis 2: per protocol
The results of the analysis are shown in Table 39. In terms of cost, standard care is, again, the least costly
strategy with a mean cost per patient estimated at £1238. The cell salvage strategy was the most effective
at avoiding a transfusion. The estimated ICER for the cell salvage strategy compared with standard care
was £8252 per donor blood transfusion avoided.
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FIGURE 4 Incremental cost-effectiveness scatterplot for donor blood transfusion avoided (ITT).
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FIGURE 5 Cost-effectiveness acceptability curve for donor blood transfusion avoided (ITT).
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The scatterplot (Figure 6) shows that although cell salvage is a more effective transfusion strategy, it is
again uncertain whether it is more or less costly than standard care. This uncertainty has been graphed
in the CEAC (Figure 7). The graph shows that if the maximum willingness to pay for a donor blood
transfusion avoided was £50,000, the probability that cell salvage was cost-effective would be 63%.
Analysis 3: emergency caesarean
The results of the analysis are shown in Table 40. The strategy in which standard care was followed
remains the least costly, but higher in comparison with the previous two analyses, with the average cost
per patient estimated at £1352. The cell salvage group had an average cost per patient estimated at
£1407, which was also slightly higher than the previous analyses. The cell salvage strategy continues to be
the most effective at avoiding a transfusion. The estimated ICER for the cell salvage strategy compared
with standard care was £13,713 per donor blood transfusion avoided.
TABLE 39 Results for the PP analysis
Transfusion strategy Average cost per patient (£) Effectiveness donor blood transfusion avoided ICER (£)
Standard care 1238 0.967
Cell salvage 1330 0.978 8252
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FIGURE 6 Incremental cost-effectiveness scatterplot for donor blood transfusion avoided (PP).
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FIGURE 7 Cost-effectiveness acceptability curve for donor blood transfusion avoided (PP).
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The scatterplot (Figure 8) shows again that although cell salvage is a more effective transfusion strategy, it
remains uncertain whether it is less or more costly than standard care. The CEAC (Figure 9) shows that the
probability that cell salvage is cost-effective remains between 47% and 55% as the willingness to pay for
a donor blood transfusion avoided increases.
TABLE 40 Results for the emergency-caesarean analysis
Transfusion strategy Average cost per patient (£) Effectiveness donor blood transfusion avoided ICER (£)
Standard care 1352 0.986
Cell salvage 1407 0.990 13,713
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FIGURE 8 Incremental cost-effectiveness scatterplot for donor blood transfusion avoided (emergency only).
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FIGURE 9 Cost-effectiveness acceptability curve for donor blood transfusion avoided (emergency only).
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Sensitivity analysis
Deterministic sensitivity analysis
As demonstrated in Table 41, the results of the deterministic sensitivity analysis were as follows:
1. Varying the cost of consumables to those used by NICE had a marginal impact on the ICER in each
analysis. Similarly, including acquisition costs in the analysis had only a minimal impact on the ICER.
In the trial, 202 centres used a continuous transfusion cell-saver machine that required different
consumables to the ones included in the main analyses. The impact of including costs for the
consumables used by this machine, when the machine is only set up for processing in patients having
blood returned and when swab washing is not conducted, resulted in an ICER of £1022 in analysis 1,
£1184 in analysis 2 and a dominant ICER in analysis 3 (i.e. cell salvage was considered less costly and
more effective than standard care).
2. In this sensitivity analysis, the cost of additional staff called into theatre solely for the purposes of cell
salvage was removed. This reduced the ICER to £7065 in the ITT analysis, £7210 in the PP analysis and
£10,932 in the emergency-caesareans analysis.
3. Raising the cost of a three-unit transfusion of RBCs to £1500 reduced the ICER by £974 in both
analyses 1 and 2 and it reduced the ICER by over £1000 in analysis 3. Threshold analysis showed that
for cell salvage to be considered cost-effective, the cost of a transfusion would have to be £8637 in
analysis 1, £8778 in analysis 2 and £13,186 in analysis 3.
TABLE 41 Deterministic sensitivity analysis
Deterministic sensitivity analysis Original value
Revised
value Original result
Cost per donor blood transfusion
avoided
Analysis 1 Analysis 2 Analysis 3
£8110 £8252 £13,713
Revised result
1. Equipment and disposables required for the cell salvage procedure
Applying the cost of consumables
(collection set + processing pack)
used by NICE
£118.71 £119.75 £8205 £8346 £13,952
Including acquisition costs based on
Haemonetics Cell Saver machine
– £22.13 £10,114 £10,246 £18,805
Using a continuous transfusion cell
saver when the machine is only set
up for processing in patients having
blood returned and swab washing is
not conducted
Cell salvage Control
£125.14 £126.40 £34.73 £1022 £1184 Dominates
2. Staff
No additional member of staff being
called into theatre solely for the
purposes of cell salvage
Cell salvage Control £0 £7065 £7210 £10,932
£11.57 £12.03
3. Donor blood
Variation in the estimate of the cost
of a three-unit RBC transfusion
£520 £750 £7886 £8028 £13,330
£1000 £7636 £7778 £13,080
£1250 £7386 £7528 £12,830
£1500 £7136 £7278 £12,580
For cell salvage to be considered cost-effective in this model the price of a three-unit
RBC transfusion would have to be:
£8637 £8778 £13,186
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Discussion
Principal findings
The results of this economic evaluation suggest that routine cell salvage is more costly than standard care
with the average cost per patient estimated at £1327 compared with £1,244. The ICER of this strategy
compared with standard care is approximately £8110 to avoid a donor blood transfusion. The PSA
suggests that at a willingness-to-pay threshold of £50,000, the probability of routine cell salvage being
cost-effective is 62%. The results of this analysis were shown to be robust for the majority of deterministic
sensitivity analyses with one exception: using a cell salvage machine that required different consumables to
those included in the main analyses, when the machine is only set up for processing in patients having
blood returned and when swab washing is not conducted, resulted in a significant effect on the ICER,
reducing it to £1022 per donor blood transfusion avoided.
A PP analysis produced an ICER of £8252 per transfusion avoided, but this result should be considered
with caution as the population in this analysis is a subset of the ITT population who completed the study
without any major protocol violations.83 In clinical practice, uptake of cell salvage is unlikely to be ‘PP’.
In a third analysis, looking at emergency caesareans only, cell salvage appears to be more effective than
standard care for avoiding a donor blood transfusion but the resulting ICER of £13,713 is driven by the
increased probability that these patients will require a higher level of postoperative care.
Strengths and limitations of the economic evaluation
The strength of this model-based economic evaluation is that it was based on a rigorously conducted RCT.
The cost and outcome data measures that were incorporated into the model were collected prospectively
during the RCT using forms filled out at the pre, intra- and postoperative phases and at the time of
discharge from hospital. In addition, the economic evaluation benefited from significant clinical and
statistical input throughout its design and development. All assumptions used in the model were agreed
with the trial team before the analysis was carried out and without knowledge of how these assumptions
would affect the results.
In terms of limitations, not all potential outcomes have been included because of the limited time scale in
our model and the lack of long-term data, for example, we could not account for long-term implications
relating to FMH as data relating to this were not available from the trial. In addition, information relating
to the clinical status and care of the infant was not included in the analysis. A further limitation of the
evaluation is that outcomes were expressed in terms of clinical effectiveness rather than in terms of a
standard unit of benefit: the QALY. Finally, the use of platelets and other blood products has not been
included in the evaluation. However, the results of the sensitivity and threshold analyses demonstrated
that including these costs would not have had an impact on the cost-effectiveness results.
Strengths and weaknesses in relation to other studies
To date, and to our knowledge, there has only been one, small, RCT looking at the elective use of cell
salvage at caesarean section44 and this study did not include an economic element. A Cochrane review of
cell salvage in adult elective surgery assessed the clinical effectiveness and cost-effectiveness of cell salvage
and other autologous transfusion strategies in elective surgery.21 It suggested that cell salvage may be an
‘effective and cost-effective alternative to the allogeneic blood transfusion strategy’. However, no obstetric
papers were identified for this review.
Meaning of the economic evaluation
The results of the economic evaluation suggest that although cell salvage is a marginally more effective
strategy than standard care in avoiding a donor blood transfusion, it is unlikely that cell salvage would be
considered cost-effective. However, the results in natural units of cost per transfusion avoided are difficult
to interpret and are very subjective. They will vary depending on the context. The lack of long-term data
on the health and quality of life of patients in both groups of the trial means that further research is
needed to fully understand the cost implications of both strategies. For patients undergoing an emergency
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caesarean section, when cell salvage is performed using a continuous transfusion cell-saver machine,
the machine is only set up for processing in patients having blood returned; and when swab washing is not
conducted, cell salvage would be considered less costly and more effective than standard care. However,
this scenario is not necessarily generalisable; therefore, this result should be interpreted with caution.
Unanswered questions and future research
The current evaluation has used data from a large, multicentre RCT that demonstrated modest evidence
that routine use of cell salvage during caesarean section reduced the need for donor blood transfusion.
The main cause of uncertainty relates to the cost implications of adopting cell salvage in routine practice.
Future studies should explore the long-term health and economic impacts associated with both transfusion
strategies. In addition, evidence on the preferences of women needs to be considered. For example,
hospitals may wish to have the option of cell salvage available for Jehovah’s Witness patients, for whom
there is no option to use donor blood.
Finally, and related, the issue of donor blood as a limited resource needs to be considered. It is important
to remember that transfusion with cell salvage can always exist, but we have not considered this in
our evaluation. Although there is an expectation that donor blood will always be there when needed,
transfusion using donor blood cannot be guaranteed. In such a scenario, when the option of donor blood
is limited or not available, the routine use of cell salvage would dominate (less costly and more effective)
standard care.
The routine use of cell salvage during caesarean section reduces, to some extent, the need for donor
blood. Whether or not this treatment strategy is also cost-effective will depend on one hand, on the cost
of a donor blood transfusion and, on the other hand, the operating cost of the cell salvage procedure.
Implementation and more efficient operation of cell salvage machines in routine care could reduce the
associated costs. At the current price level of donor blood and operating costs of cell salvage, cell salvage
appears to be a more costly strategy to reduce the use of donor blood and only when the price of a blood
transfusion increases to levels beyond £8637 does cell salvage potentially become a cost-effective strategy.
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Chapter 5 Discussion
Aim and overview
The provision of a reliable donor blood transfusion service has critical implications for maternal health.
In health-care systems in which this is available, maternal mortality due to haemorrhage is almost one
thousand fold less than in those in which it is not.86,87 Donor blood transfusion is a safe intervention with
remarkably few associated AEs, although these may be serious and even, although rarely, fatal. In the face
of such a proven clinical intervention, any new technique seeking to further reduce mortality would have
to be extremely effective and require an unfeasibly large trial in order to demonstrate it. Despite these
limitations to evaluation of a new technology, for many clinicians this would be intuitively considered the
aim of introducing cell salvage into obstetric clinical practice. More realistically, cell salvage might reduce
reliance on donor blood, the production and delivery of which remains relatively expensive (£120 per
unit78) and while representing a ‘pooled’ national resource, may suffer from local hospital shortages
when consumption is increased by a case of unexpected severe haemorrhage. However, cell salvage is a
technology with its own costs and, therefore, it was clear from the outset of the SALVO trial that the
health economic evaluation would be a crucial aspect of the trial, in order to show a worthwhile reduction
in spend on donor blood units that was greater than the cost of the intervention. With an increasing
reluctance to transfuse donor blood to even quite substantially anaemic women, owing to the possible
adverse effects, cell salvage offered the possibility of safely increasing postoperative haemoglobin levels,
leading to additional savings in patient care and hospital stay. These again, required rigorous health
economic evaluation to provide meaningful conclusions, particularly as other clinical interventions88 for
optimising preoperative haemoglobin levels (e.g. iron therapy) or reducing intraoperative blood loss
(e.g. tranexamic acid or interventional radiology) may be cheaper and more efficacious.
A number of end points were considered as candidates for a primary outcome. The selection of transfusion
rate was ultimately a pragmatic one, based on objectiveness, ease of collection and the existence of
pre-existing data. In addition, a patient questionnaire given to women who had undergone the procedure
highlighted the reassuring nature of receiving one’s own blood instead of donor blood [see original SALVO
protocol (URL: www.journalslibrary.nihr.ac.uk/programmes/hta/105732#/ (accessed August 2017)].
Main findings
This large, multicentre RCT demonstrated modest evidence that routine, prophylactic use of cell salvage
during caesarean section reduced the need for donor blood transfusion. It was associated with increased
maternal exposure to fetal blood among Rh-negative mothers. Small differences were observed between
groups for time to mobilisation and length of hospital stay but not in other secondary outcomes. Although
numerically there appeared to be a greater effect in the emergency group compared with the elective
group, the difference in effect between subgroups was not statistically significant. Exploratory analysis did
not suggest a subgroup benefit in women with abnormal placentation. Although it appeared to increase
the volume of salvaged blood returned, the use of ‘swab washing’ when conducting cell salvage did not
appear to affect the need for donor blood transfusion.
Health economic analysis demonstrated that it would cost £8110 to avoid a blood transfusion with
the use of cell salvage as used in the study. This cost could potentially be reduced by varying both the
indication for cell salvage in caesarean section and by changing the technique used. Set-up for a continuous
cell-saver machine, with ‘collection’ only, until sufficient volume was obtained for processing, could save the
cost of the processing consumables. Swab washing could be relinquished as a technique, as it did not
appear to have any effect on donor blood transfusion rate.
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Strengths and limitations of the trial
To our knowledge, the SALVO trial is the largest multicentre evaluation of cell salvage in caesarean section
to date. The RCT was prospectively registered, robustly conducted, independently monitored, rigorously
analysed and transparently reported (see Figure 2). This should provide for confidence in validity and
reliability of the findings. The study sample was diverse, spread across more than 20 UK centres.
Only two indications for caesarean section were considered exclusions: first elective caesarean section for
either breech or maternal request. The very low probability that these cases might require donor blood
meant that excluding them left only women with a recognisable increased risk of haemorrhage and, thus,
potential need for transfusion, increasing the power of the study to detect a difference. This broad base
for inclusion adds to the generalisability of the findings.
The trial recruited to target and had comparability at baseline and compliance with assignment, minimal
loss on follow-up and primary outcome. A substantial challenge to the conduct of an individually
randomised trial is obtaining consent from women in labour who require emergency caesarean.89,90
Therefore, meeting the target for recruitment in a challenging clinical context was a major achievement.
We considered this group to be the one most likely to derive specific benefit from this health technology.
Another challenge was the promotion of equipoise among participating clinicians, who were keen to
adopt the technology, without robust evidence in cases for which anxiety for life-threatening haemorrhage
was high, particularly for cases of abnormal placentation.
Owing to the nature of the intervention and because mothers are usually awake for caesarean section, it
was considered impractical to formally blind either clinicians or patients to the group allocation. In view of
this and the local variation in transfusion practices, the trial collected transfusion policies from each unit
and then reviewed transfusion decisions in light of these. Although clinicians were found to commonly
give donor blood in deviation to local policy, no difference was found in the rate with which this
non-adherence to local policy occurred between intervention and control groups.
A criticism of sample size and power with presumption of likelihood of type II error could risk erroneous
conclusions. We highlight that a p-value that is in the region of a 0.05, regardless of the side of the
threshold in which it lies, deserves careful consideration with respect to use of the evidence for guiding
practice. The failure to achieve statistical significance cannot be attributed to insufficient data when the
study is completed to the planned size with independent monitoring. We would like to propose the
following considerations in interpretation of our main finding: (1) addition of new data does not guarantee
that the p-value threshold for significance will be reached91 and (2) the point estimate is the most plausible
estimate of the true effect. This being the case, we believe that our main finding meets the criteria for
accurate decision-making.
From the outset, we were aware that we were investigating the effect of an intervention in a heterogeneous
population in terms of baseline risk. This heterogeneity is principally derived from the indication for
caesarean section. This situation guided the use of covariate-adjusted and subgroup analyses as an integral
part of trial planning, analysis and inference. The credibility of findings in subgroup analysis depends on a
number of factors. We planned these a priori and limited the number of subgroup analyses to the bare
minimum in order to limit the risk of spurious significance associated with multiple hypothesis testing.
Caution must be exercised in the conduct and interpretation of evidence derived from subgroup analysis;
however, not investigating or ignoring results of subgroup analyses could also lead to incorrect inferences.
Although interaction proved statistically insignificant, suggesting no evidence for an inconsistent effect of
cell salvage between elective and emergency cases, taking into account the observed point estimates and
CIs from subgroup analyses for the primary outcome measure, we believe that our findings concerning the
effect in emergency caesareans merit consideration.
The role of our sensitivity analysis was to evaluate the integrity of the primary analysis conducted based on
the ITT principle. The design and analysis was predicated on adherence to assignment, whether control or
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cell salvage. We sought for consistency between the results of primary analysis and the results of sensitivity
analysis to examine the credibility of the main finding. We planned a priori to assess if the erroneous
return of cell-salvaged blood in the control group could potentially avert the use of donor transfusion.
In the throes of a developing surgical emergency, it may be thought of as a useful intervention to deal
with ongoing haemorrhage by clinicians handling cases in the control group. We could not prevent such a
clinical intervention in an ethically consistent trial policy. Therefore, we proposed to reclassify such cases
as having experienced the primary outcome. Study structures and team members strove to promote
adherence to assignment but protocol deviations are common in pragmatic trials and several cases
assigned to the control group did indeed receive salvage, even in the absence of such an acute emergency
situation. One proposal to handle this problem could include alternative trial designs, such as cluster
randomisation, but this approach does not necessarily guarantee avoidance of performance bias and
generally reduces statistical power. Our approach to sensitivity analysis maintained the ITT principle,
avoiding PP and as-treated analyses that have a tendency to produce spurious significance. Our sensitivity
analyses confirmed the main finding for the primary outcome.
The SALVO trial studied both emergency and elective (planned) caesarean sections, despite the fact that
owing to a higher incidence of haemorrhage in the former, a significant result might be more likely to be
detected if the trial had excluded electives. There were two reasons for this. First, some centres were known
to have already commenced using cell salvage routinely for elective cases in the absence of any evidence, so
the question of evaluating effectiveness in this group remained pertinent. Second, emergencies represented
a population much more challenging to recruit. The elective sample gave centres the opportunity to deploy
and prove the trial processes in a much more straightforward population. Despite this, two groups of
electives were known to have extremely low rates of haemorrhage and were therefore excluded (first
caesareans for either breech or maternal request). The effect of cell salvage in the emergency group, while
non-significant with regards to interaction with the elective group, will be interesting to clinicians. On the
other hand, the finding of no effect in the placental abnormalities subgroup is less relevant for policy as
guidance already exists for use of salvage in these high-risk cases.40
At the time that the SALVO trial was conceived and designed, cell salvage techniques used in obstetrics
were markedly heterogeneous and dependent on local attitudes and expertise. It was clear from the outset
that a robust trial would require close to optimal use of the intervention in order for the results to be
accepted by the clinical community. Optimal use in this context maximises the volume of salvaged blood
returned to the mother. Therefore, a number of technical aspects of the machine use were made mandatory
for trial patients to achieve this aim. Some other aspects that might increase blood return were left to local
preference, as it was felt that it would be difficult to commission enough recruiting centres to complete
the study if these technical elements of cell salvage management were made mandatory. Subgroup analysis
of swab washing failed to show any effect on the primary outcome. We conclude that there are no other
identifiable mechanisms, utilising current cell salvage technology, which might significantly increase the
return of salvaged blood to the patient compared with trial practices capable of casting any doubt on the
validity of our results.
External validity and generalisability
We consider the external validity of the SALVO trial to be very robust. It was conducted in a broad group of
obstetric units, ranging from large, tertiary teaching hospitals to small district general hospitals. It recruited
from a diverse range of indications for caesarean section, with few exclusion criteria. The nature of the
intervention was maintained as pragmatic as possible, consistent with efficacy and adequate recruitment,
yet delivered in a predictable manner that is easy to emulate outside the context of a trial. The adherence to
protocol was higher than expected for an intervention that had already begun to enter routine practice with
a consequent potential loss of equipoise when the trial commenced.
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Red cell immunisation
The UK SHOT haemovigilance scheme has repeatedly highlighted suboptimal practice in relation to the
management of anti-D prophylaxis in cases of caesarean section with rhesus incompatibility.92 They have
stressed the need for improved awareness of national guidelines, supported by education and training
among all health-care professionals involved.92 We had the novel opportunity to observe practice around
anti-D prophylaxis, in relation to cell salvage in particular.
Although total omissions of anti-D prophylaxis after delivery occurred in only a small number of cases in
either group (total n = 3), there are many other opportunities for improved adherence to national
guidelines, in particular regarding the recommended minimum anti-D dose of 1500 IU following cell
salvage34 and the need for FMH testing to assess if further anti-D is needed beyond the standard dose.
This highlights a need for close communication between clinicians and laboratory teams to ensure that
relevant testing is undertaken followed by subsequent appropriate management to minimise the risk of
RhD sensitisation.
Although secondary analysis indicated a significantly higher risk of FMH of ≥ 2 ml based on Kleihauer testing
in the cell salvage group, the clinical implications of this result are unclear. We have incomplete data on flow
cytometry results to confirm FMH volumes. Further analysis of available results indicate that the majority of
women with bleeds > 4 ml did receive appropriate doses of anti-D with further follow-up testing to check
for fetal red cell clearance as per guidelines, but there were some omissions. We are unable to comment on
the overall efficacy of anti-D prophylaxis and the subsequent risk of RhD sensitisation. The SHOT scheme is
currently collecting data on all pregnant women who have produced immune anti-D detected for the first
time, to better understand the reasons underlying RhD sensitisation.
Although we are unable to comment on the risk of alloimmunisation to other red cell antibodies following
cell salvage as opposed to standard care, our data support the assertion that the use of cell salvage
significantly increases the risk of FMH. When just the women receiving cell-salvaged blood are considered,
the rate of FMH, based on the definition used in the study, is more than four times that of the control group.
The implications of this may go beyond the increased cost of a larger anti-D dose required in women
receiving cell-salvaged blood. Although we did not specifically study other red cell antigens, it is plausible and
likely that this increased FMH would cause increased rates of introduction of these antigens into the maternal
circulation. As no anti-D equivalent is available for these antigens, maternal antibody formation will not be
avoided and these antibodies (e.g. anti-Kell) may make cross matching blood for these women significantly
more difficult in the future, incurring additional health-care costs. As the rate and severity of these potential
complications is completely unknown, we were unable to incorporate it into our health economic analysis.
Adverse and serious adverse events
The AEs and SAEs were spread evenly across the two groups. An increase in the rate of AFE has long been
considered a potential AE of returning cell-salvaged blood at caesarean section, even though research
indicates it is removed by the cell saver. It is reassuring that we did not observe any cases of AFE in either
group, but particularly not in the subgroup who actually received salvaged blood back, whether or not a
LDF was used. It is notable that all the AEs definitely or probably related to cell salvage occurred when a
LDF was in use, consisting of acute haemodynamic and respiratory reactions to the return of salvaged
blood. These reactions have been well reported in the literature and are thought to be due to an effect the
filter induces on the salvaged blood, rather than due to the blood per se.18,23–26 We did not observe any
definitely or probably cell-salvage-related AEs when a filter was not used. Out of the 15 possibly related
AEs, a filter had been used in 13. These included a range of AEs, including infective and haemorrhagic
complications that could easily have been unrelated to the use of cell salvage. Ultimately, it was for the
local principal investigator to make this judgement on relatedness. There was one case of reaction to
donor blood in the control group, from which the mother made a full recovery. This is in keeping with the
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known rates of reaction.18 One maternal death occurred in a trial participant, who had been allocated to
the cell salvage intervention group. A local case review was carried out by the trust involved and did not
find any link to the use of cell salvage.
Adverse events from donor blood transfusion are potentially serious but are also very rare, with a rate of 1 in
16,000.18 Mortality associated with donor blood transfusion is even more uncommon, with a rate of 1 in
100,000.18 We have demonstrated that the cost to avoid a transfusion event when routinely using cell
salvage in caesarean section is £8110. When considered with the observed increase in FMH and potential
long-term effects of this, which currently remain uncharacterised, it remains unclear whether or not cell
salvage is beneficial in this patient group. The exception to this is in cases such as for Jehovah’s Witnesses,
for whom donor blood cannot be used and cell salvage represents the only therapeutic option. We are also
unable to comment on the specific benefit in the group at a high risk of torrential haemorrhage such as
placenta accreta, as we had insufficient recruits in this group to come to any meaningful conclusions.
Conclusions
Implications for health-care service
l Cell salvage may reduce the need for donor blood transfusion. It is unlikely to be considered cost-
effective when routinely set up for use in caesarean section. The cost-effectiveness varies by indication
for caesarean section and cost of cell-saver technique used.
l In RhD-negative mothers having RhD-positive babies, there appears to be an increased chance of FMH
when cell-salvaged blood is returned to the mother, which needs to be taken into consideration with
regard to applying and updating guidance on the use of anti-D prophylaxis. Our findings highlight the
need for increased vigilance and appropriate prevention of the risk of RhD-isoimmunisation among
RhD-negative mothers.
l If cell salvage continues to be used in groups such as Jehovah’s Witnesses and those with placenta
accreta, women should be counselled about the balance of risks in using cell salvage.
Recommendations for further research
l The effect of increased FMH associated with cell salvage on the incidence of rarer, non-RhD red cell
antigens needs to be characterised and quantified in the long term.
l Investigation is needed to determine if greater amounts of routine anti-D administration are required
when cell salvage has been used on RhD-negative mothers.
l Additional factors (e.g. swab washing or number of suckers used) that may increase the likelihood of
blood return during use of cell salvage should be investigated.
l The effectiveness of cell salvage in specific subgroups, such as those with placenta accreta, remains to
be investigated.
l The role of cell salvage in low- to middle-income countries, where caesarean rates are rising and blood
transfusion services are not well developed, should be investigated.
l If new, cheaper or more efficient cell salvage technology becomes available, the conclusions of the
SALVO trial may need to be revisited. The same is true if donor blood shortages should become
extreme and acute.
l Recent and ongoing research into the use of tranexamic acid and other strategies to prevent or
manage maternal anaemia to make caesarean section safer will merit consideration in practice and
future research alongside our findings.88
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Appendix 1 List of participating sites and the
SALVO research staff
l Barts Health Trust, London:
¢ Royal London Hospital
¢ Whipps Cross University Hospital
¢ Matthew Hogg (principal investigator), Sajith Philip, Sarah Weist, Felipe Castro Cardona,
Heike Bojahr, Lilith Loncke and Prudence Jones.
l Royal United Hospitals Bath NHS Foundation Trust:
¢ Royal United Hospital, Bath
¢ Chris Marsh (principal investigator), Sara Burnard, Wendy Duberry, Elly Doyle, Karen Patrick,
Catherine Bressington, Jenny Pullen, Mel Rich, Jess Withers and Amy Lloyd.
l Heart of England NHS Foundation Trust:
¢ Birmingham Heartlands Hospital
¢ Nicky Osborn (principal investigator), Ahmed Mesbah, Katie Trowman, Linda Bradley,
Katie Atterbury and Teresa Melody.
l Birmingham Women’s NHS Foundation Trust:
¢ Birmingham Women’s Hospital
¢ James Geoghegan (principal investigator), Philip Moore, Chloe O’Hara and Elizabeth Ewer.
l University Hospitals Bristol NHS Foundation Trust:
¢ St Michael’s Hospital, Bristol
¢ Isobel Gardner (principal investigator), Carole Shahin, Alison Kirby, Mariethel Gudaca,
Eirini Troupkou, Colleen Hunt, Claire Dowse, Nicola Harvey, Nicolas Wharton and Mark Scrutton.
l Chelsea and Westminster Hospital NHS Foundation Trust:
¢ West Middlesex University Hospital, Isleworth
¢ Dominika Dabrowska (principal investigator), Marie O’Connell, Bernadette Tilley, Catherine Sheehan,
Philip Barclay, Christine Adamson, Mehari Teklay, Sherif Omran, Sujatha Vishvanath, Amanpreet Sarna,
Sheldon Zhang, Rafiu Ojo, Lisa Takab, Tina Brough, Emma Fox, Sarah Barker, Ano Rathambegoda,
Edward Twumasi, Jacob Sheen, Belinda White, Wilky Ian Nunal and Emmanuel Espiritu.
l Croydon Health Services NHS Trust:
¢ Croydon University Hospital
¢ Bini Ajay (principal investigator), Dhileepan Srinivasan, Temilola Doherty, Valerie Fuller, Tony Hewitt,
Ramandeep Sharma, Ajeet Kumar, Rebecca Byrne and Vana Wardley.
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l NHS Lothian:
¢ Simpson Centre for Reproductive Health, Edinburgh
¢ Vicki Clark, Arlene Wise (principal investigators), Ida Hassing and Karen Edgar.
l Hinchingbrooke Health Care NHS Trust:
¢ Hinchingbrooke Hospital
¢ Sangeeta Pathak (principal investigator), Tara Pauley, Charlotte Clayton and Aarti Bahirat.
l Leicester University Hospitals NHS Trust:
¢ Leicester Royal Infirmary
¢ Leicester General Hospital
¢ Tommy Mousa (principal investigator), Molly Patterson, Sharon Bates, Jo Dickens, Katie Peck,
Anna Muggleton, Claire Dodd, Asma Rabab, Tina Evans, Tracey Bryan, Magda Kierzenkowska,
Margaret Weston, Sarah Clarke, Katie Warwick, C Elton, P Sharpe, A Morris, P Ramasamy, E Hart,
R Leighton, O Navti and O Joseph.
l South Tees Hospitals NHS Foundation Trust:
¢ James Cook University Hospital, Middlesbrough
¢ Sanjay Rao (principal investigator), Aethele Khunda and the research team, Hazel Alexander,
Sarah Croft, Obstetric Consultants and Anaesthetists, Speciality Trainees, Labour Ward Midwifery
team and Theatre team.
l The Newcastle upon Tyne Hospitals NHS Foundation Trust:
¢ Royal Victoria Infirmary, Newcastle
¢ Paul Ayuk (principal investigator), Sophia Webster, Jill Sturt, Celia McKee, Angela Yulia, Andrea Fenn,
Michelle Perkins, MaCassie Galeon, Jill Riches, Cat Rowney, Erica Del Prete, Sue Harbertson,
Terri Brosnan, Sharon Chilton, Victoria Murtha, Jenna Wall, Emma Schultz, Alison Bates and
Nicola King.
l Norfolk and Norwich University Hospitals NHS Foundation Trust:
¢ Norfolk and Norwich University Hospital
¢ Maria del Rocio Ochoa-Ferraro (principal investigator), Elizabeth Turner, Jonathon Francis,
David Thornton, Carole Winstanley, Jeremy Corfe and Rachel Appleton.
l London North West Healthcare NHS Trust:
¢ Northwick Park Hospital
¢ Parijat Bhattacharjee (principal investigator).
l Nottingham University Hospitals NHS Trust:
¢ Queens Medical Centre, Nottingham
¢ Nottingham City Hospital
¢ Lesley Woods (principal investigator), Jim Thornton (a member of the NIHR HTA Editorial Board),
George Bugg, Sujata Handa, Arani Pillai, Yvette Davis, Yvonne Toomassi, Yvette Gunn,
Denise Lochrie and Carys Smith.
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l Plymouth Hospitals NHS Trust:
¢ Derriford Hospital, Plymouth
¢ Darryl Thorp-Jones (principal investigator), Heidi Hollands, Jocelyn Watson, Alison Stolton and
Amanda Carney.
l Barking, Havering and Redbridge University Hospitals NHS Trust:
¢ Queen’s Hospital, Romford
¢ Vinod Patil (principal investigator), Annemarie McGregor, Rebecca Murray, Dorothy Sutton,
Theresa McCluskey, Julie Wright, Molly Murwira, Sue Rogers and Mark Beaufond.
l Sheffield Teaching Hospitals NHS Foundation Trust:
¢ Royal Hallamshire Hospital, Sheffield
¢ Ian Wrench (principal investigator), Siobhan Gillespie, Carolyn Clark, Emma Steel, Sarah Senbeto,
Paula Woodcock, Tessa Bonnett, Nicola Cawley and Hannah Yeeles.
l University Hospitals of North Midlands NHS Trust:
¢ Royal Stoke University Hospital, Stoke-on-Trent
¢ Jules Allt (principal investigator), Charlotte Howell, Siby Sebastian, A Rajashanker, Angela Rooney,
Sara Mountford, Suzanne Jerreat, Amanda Redford, Anna Fleming, Donna Brayford, Wendy Dudley,
Sarah Elson, Rachel Sparkes, Andrea Vickers, Chris Hollins, N Butler, S Scally, Theresa Webbon,
Susan Bell, Andrea Morgan, Brett Beasley and MJ Newton.
l City Hospitals Sunderland NHS Foundation Trust:
¢ Sunderland Royal Hospital
¢ Aarti Ullal (principal investigator), Kim Hinshaw, Helen Cameron, Kirsten Herdman, Eileen Walton,
Gill Campbell, Lesley Hewitt, Deborah Bonney, Kathleen Hubbard, Karen Armstrong, Judith Ormonde,
Joanne Knight, Kathryn Witte, Dawn Edmundson, Sonia Thompson, Denise Mace, Sharon Morrell,
Suzanne Stelling, Marion Collings, Julie Harris, Amanda Bargh, Judith Holland, Chris Field and
Catherine Parkinson.
l Abertawe Bro Morgannwg University Health Board:
¢ Singleton Hospital, Swansea
¢ Susan Williams (principal investigator), Sue Catling, Sharon Jones, Trudy Smith, Helen Worrell and
Sarah Fox.
l Torbay and South Devon NHS Foundation Trust:
¢ Torbay Hospital
¢ David Portch (principal investigator), Richard Hughes, Shakila Sudhaker, Jeremy Ackers,
Pauline Fitzell and Janet Palmer.
l St Helens and Knowsley Teaching Hospitals NHS Trust:
¢ Whiston Hospital, Prescot
¢ Peter Yoxall (principal investigator) and Zoe Grindley.
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Appendix 2 Recruitment graphs
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FIGURE 10 Overall recruitment graph.
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FIGURE 11 Recruitment graph by caesarean section type.
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